Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Feb. 23, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	VTVT
Entity Registrant Name	vTv Therapeutics Inc.
Entity Central Index Key	0001641489
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 33,577,419
Class A Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		9,693,254
Class B Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		23,119,246

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 11,758,000	$ 51,505,000
Restricted cash and cash equivalents	162,000	0
Accounts receivable, net	8,000,000	0
Prepaid expenses and other current assets	442,000	612,000
Total current assets	20,362,000	52,117,000
Restricted cash and cash equivalents, long-term	2,500,000
Property and equipment, net	283,000	444,000
Long-term investments	2,480,000
Long-term deposits	2,292,000	1,934,000
Total assets	27,917,000	54,495,000
Current liabilities:
Accounts payable and accrued expenses	13,901,000	11,413,000
Current portion of deferred revenue	8,757,000	21,000
Current portion of notes payable	4,271,000
Total current liabilities	26,929,000	11,434,000
Notes payable	15,316,000	11,058,000
Deferred revenue, net of current portion	4,497,000
Warrant liability, related party	492,000
Other liabilities	290,000	433,000
Total liabilities	47,524,000	22,925,000
Commitments and contingencies
Redeemable noncontrolling interest	131,440,000	122,515,000
Stockholders’ deficit:
Additional paid-in capital	127,682,000	124,212,000
Accumulated deficit	(279,058,000)	(215,486,000)
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	(151,047,000)	(90,945,000)
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit	27,917,000	54,495,000
Class A Common Stock [Member]
Stockholders’ deficit:
Common stock value	97,000	97,000
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	97,000	97,000
Class B Common Stock [Member]
Stockholders’ deficit:
Common stock value	232,000	232,000
Total stockholders’ deficit attributable to vTv Therapeutics Inc.	$ 232,000	$ 232,000

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Aug. 04, 2015	Jul. 29, 2015
Class A Common Stock [Member]
Common stock par value	$ 0.01	$ 0.01			$ 0.01
Common stock, shares authorized	100,000,000	100,000,000			100,000,000
Common stock, shares outstanding	9,693,254	9,693,254	9,156,686
Class B Common Stock [Member]
Common stock par value	$ 0.01	$ 0.01		$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000			100,000,000
Common stock, shares outstanding	23,119,246	23,119,246	23,655,814

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 291,000	$ 634,000	$ 519,000
Operating expenses:
Research and development	39,640,000	44,953,000	27,237,000
Research and development – related party		795,000	2,347,000
General and administrative	11,333,000	9,906,000	9,077,000
Total operating expenses	50,973,000	55,654,000	38,661,000
Operating loss	(50,682,000)	(55,020,000)	(38,142,000)
Other income (loss)		(22,000)	(838,000)
Other expense – related party	(190,000)		(392,000)
Interest income	117,000	87,000	40,000
Interest expense	(3,092,000)	(398,000)	(108,000)
Interest expense, net – related party			(1,667,000)
Loss before income taxes and noncontrolling interest	(53,847,000)	(55,353,000)	(41,107,000)
Income tax provision	800,000	0	0
Net loss before noncontrolling interest	(54,647,000)	(55,353,000)	(41,107,000)
Less: net loss attributable to noncontrolling interest	(38,503,000)	(39,001,000)	(13,609,000)
Net loss attributable to vTv Therapeutics Inc.	$ (16,144,000)	$ (16,352,000)	$ (27,498,000)
Class A Common Stock [Member]
Operating expenses:
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (1.67)	$ (1.71)	$ (3.32)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	9,693,254	9,545,527	8,276,520

Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Noncontrolling Interest, Stockholders' and Members' Deficit - USD ($) $ in Thousands	Total	TransTech Pharma, LLC (TTP) [Member]	Redeemable Convertible Preferred Units [Member]	Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Redeemable Noncontrolling Interest [Member]	Class A Common Stock [Member]	Class B Common Stock [Member]	Members Deficit [Member]	Members Deficit [Member] TransTech Pharma, LLC (TTP) [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2014	$ (498,806)							$ (498,806)
Beginning balance, redeemable convertible preferred units at Dec. 31, 2014			$ 438,086
Net loss	(27,498)
Net loss prior to the Reorganization Transactions	(22,111)							(22,111)
Change in redemption value of TTP redeemable convertible preferred units		$ (75,077)		$ 75,077					$ (75,077)
Effect of Reorganization Transactions	596,244		$ (513,163)		$ (2,997)		$ 250	$ 595,994
Effect of Reorganization Transactions, shares							25,000,000
Issuance of Class A Common Stock in initial public offering, net of offering costs	104,445					$ 79				$ 104,366
Issuance of Class A Common Stock in initial public offering, net of offering costs, shares						7,812,500
Net loss subsequent to Reorganization Transactions	(5,387)				(13,609)						$ (5,387)
Share-based compensation	859									859
Exchange of Class B Common Stock for Class A Common Stock	12,461				(12,461)	$ 13	$ (13)			12,461
Exchange of Class B Common Stock for Class A Common Stock, shares						1,344,186	(1,344,186)
Change in redemption value of noncontrolling interest	(190,598)				190,598						(190,598)
Ending balance at Dec. 31, 2015	(77,970)					$ 92	$ 237			117,686	(195,985)
Ending balance, redeemable noncontrolling interest at Dec. 31, 2015					161,531
Ending balance, shares at Dec. 31, 2015						9,156,686	23,655,814
Net loss	(16,352)				(39,001)						(16,352)
Share-based compensation	2,641									2,641
Issuance of warrants to purchase Class A Common Stock	721									721
Exchange of Class B Common Stock for Class A Common Stock	3,164				(3,164)	$ 5	$ (5)			3,164
Exchange of Class B Common Stock for Class A Common Stock, shares						536,568	(536,568)
Change in redemption value of noncontrolling interest	(3,149)				3,149						(3,149)
Ending balance at Dec. 31, 2016	(90,945)					$ 97	$ 232			124,212	(215,486)
Ending balance, redeemable noncontrolling interest at Dec. 31, 2016	122,515				122,515
Ending balance, shares at Dec. 31, 2016						9,693,254	23,119,246
Net loss	(16,144)				(38,503)						(16,144)
Share-based compensation	3,645									3,645
Issuance of warrants to purchase Class A Common Stock	167									167
Issuance of Letter Agreement and warrants to purchase Class A Common Stock - related party	(342)									(342)
Change in redemption value of noncontrolling interest	(47,428)				47,428						(47,428)
Ending balance at Dec. 31, 2017	(151,047)					$ 97	$ 232			$ 127,682	$ (279,058)
Ending balance, redeemable noncontrolling interest at Dec. 31, 2017	$ 131,440				$ 131,440
Ending balance, shares at Dec. 31, 2017						9,693,254	23,119,246

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss before noncontrolling interest	$ (54,647)	$ (55,353)	$ (41,107)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Gain on disposal of property and equipment, net	(11)	(2)	(7)
Depreciation expense	197	265	501
Share-based compensation expense	3,645	2,641	859
Change in fair value of contingent distribution			695
Change in fair value of warrants, related party	190
Amortization of debt discount	1,029	154
Non-cash interest expense – distribution payable			27
Impairment loss on carrying value of land			48
Bad debt (recovery) expense – related party			(3)
Changes in assets and liabilities:
Accounts receivable	(8,000)	69	(69)
Prepaid expenses and other assets	170	502	(1,020)
Employee loans receivable – related party		49	12
Note receivable			(20)
Long-term deposits	(358)	(261)	(1,598)
Accounts payable and accrued expenses	2,448	4,786	2,930
Accounts payable and accrued expenses – related party		(880)	2,458
Deferred revenue	10,753	(198)	219
Other liabilities	24	19	(871)
Net cash used in operating activities	(44,560)	(48,209)	(36,946)
Cash flows from investing activities:
Proceeds from sale of assets	32	4	25
Purchases of property and equipment	(57)	(87)	(104)
Net cash used in investing activities	(25)	(83)	(79)
Cash flows from financing activities:
Proceeds from issuance of vTv Therapeutics Inc. Class A Common Stock sold in initial public offering, net of offering costs			105,773
Proceeds from debt issuance	7,500	12,500
Debt issuance costs		(673)
Payment of offering costs – related party			(1,329)
Proceeds from debt issuance – related party			19,289
Repayment of long-term obligations		(33)	(89)
Net cash provided by financing activities	7,500	11,794	123,644
Net decrease in cash and cash equivalents	(37,085)	(36,498)	86,619
Total cash, cash equivalents and restricted cash and cash equivalents, beginning of year	51,505	88,003	1,384
Total cash, cash equivalents and restricted cash and cash equivalents, end of year	14,420	51,505	88,003
Supplemental cash flow information:
Cash paid for interest	2,064	242	75
Non-cash activities:
Receipt of investment as partial consideration for license agreement	2,480
Change in carrying value of net assets and liabilities not transferred to vTv Therapeutics, LLC as part of the Reorganization Transactions			2,747
Change in redemption value of noncontrolling interest	(47,428)	(3,149)	(190,598)
Exchange of vTv Therapeutics Inc. Class B Common Stock and vTv Therapeutics, LLC member units for vTv Therapeutics Inc. Class A Common Stock		3,164	12,461
Issuance of Letter Agreement and warrants to purchase vTv Therapeutics Inc. Class A Common Stock to a related party	302
Issuance of warrants to purchase vTv Therapeutics Inc. Class A Common Stock		923
Redeemable Noncontrolling Interest [Member]
Non-cash activities:
Change in redemption value of noncontrolling interest	$ 47,428	$ 3,149	$ 190,598

Description of Business and Basis of Presentation

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

Note 1: Description of Business and Basis of Presentation

Description of Business

vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”), was incorporated in the state of Delaware in April 2015. The Company was formed to discover and develop orally administered small molecule drug candidates to fill significant unmet medical needs.

Initial Public Offering

On August 4, 2015, vTv Therapeutics Inc. consummated its initial public offering (“IPO”) of 7,812,500 shares of its Class A common stock, par value $0.01 per share (“Class A Common Stock”), at a price of $15.00 per share. The IPO raised net proceeds of approximately $109.0 million after underwriting discounts and commissions but before expenses. vTv Therapeutics Inc. used the net proceeds of the IPO to acquire nonvoting common units (“vTv Units”) of vTv Therapeutics LLC (“vTv LLC”), an entity created to hold substantially all of the assets and operations of vTvx Holdings I LLC (formerly known as TransTech Pharma, LLC, “TTP” or “vTvx Holdings I”) and vTvx Holdings II LLC (formerly known as High Point Pharmaceuticals, LLC, “HPP” or “vTvx Holdings II” and together with vTvx Holdings I, the “Predecessors”), which assets and operations were transferred to such entity in a series of pre-IPO reorganization transactions (the “Reorganization Transactions”). vTv LLC is an entity under common control with vTv Therapeutics Inc. The Company intends to use the net proceeds from the IPO to fund clinical development, studies, and trials for its various products and other drug candidates, for working capital and other general corporate purposes.

Reorganization Transactions

During July 2015, TTP and HPP were renamed vTvx Holdings I LLC and vTvx Holdings II LLC, respectively. Concurrent with the IPO, the Company then entered into the following Reorganization Transactions, through which the operations of vTvx Holdings I and vTvx Holdings II were combined into vTv LLC:

(1)

vTvx Holdings I and vTvx Holdings II contributed substantially all of their assets, including all of their personnel and operations (the “Contributed Assets”), to a newly formed holding company, vTv Therapeutics Holdings LLC (“vTv Therapeutics Holdings”), in return for interests of vTv Therapeutics Holdings. Assets that were not contributed included restricted cash, certain receivables unrelated to the combined operations and land included in property and equipment, net. Liabilities that were not assumed included debt, a contingent distribution payable and other related party liabilities. All assets and liabilities that were not contributed or assumed remained with vTvx Holdings I and vTvx Holdings II and are not reflected in the Consolidated Balance Sheets as of December 31, 2017 and 2016;

(2)

vTv Therapeutics Holdings contributed the Contributed Assets to vTv LLC, a newly formed Delaware limited liability company, and, for administrative convenience, vTv Therapeutics Holdings directed that the assets be transferred directly to vTv LLC on behalf of vTv Therapeutics Holdings;

(3)

vTv Therapeutics Inc. amended and restated its certificate of incorporation and by-laws to provide for two classes of common stock:

(a)

Class A Common Stock, which represents economic interests and has one vote per share, and

(b)

Class B common stock, par value $0.01 per share (“Class B Common Stock”), which represents no economic interests and has one vote per share;

(4)

vTv LLC amended and restated its limited liability company agreement (the “Amended and Restated LLC Agreement”) to provide that it has two classes of membership units:

(a)

One managing member unit, which represents no economic interests and has 100% of the voting power of vTv LLC; and

(b)

Non-voting vTv Units, which represent economic interests;

(5)

vTv LLC issued the managing member unit to vTv Therapeutics Inc.;

(6)

vTv LLC issued 25,000,000 vTv Units to vTv Therapeutics Holdings; and

(7)

vTv Therapeutics Inc. issued 25,000,000 shares of Class B Common Stock, which represents no economic interests in the Company but has the right to cast one vote per share, to vTv Therapeutics Holdings which correspond to each vTv Unit held by vTv Therapeutics Holdings.

Below is a summary of the principal documents entered into in connection with the Reorganization Transactions:

Exchange Agreement - Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv LLC, the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for (i) shares of the Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the option of vTv Therapeutics Inc. (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the “Board of Directors”). On October 5, 2015, vTv Therapeutics Holdings was dissolved, and various holders of Class B Common Stock became parties to the Exchange Agreement.

Tax Receivable Agreement - The Tax Receivable Agreement among the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.

Investor Rights Agreement - The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration rights with respect to its shares of Class A Common Stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A Common Stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.

On October 1, 2015, vTvx Holdings I and vTvx Holdings II merged with and into vTv Therapeutics Holdings, with vTv Therapeutics Holdings continuing as the surviving limited liability company. On October 5, 2015, vTv Therapeutics Holdings was dissolved and made a liquidating distribution of shares of Class B Common Stock and the corresponding vTv Units to its members. As a result of the dissolution, M&F TTP Holdings LLC became the successor to vTv Therapeutics Holdings under the Investor Rights Agreement, the Exchange Agreement and the Tax Receivable Agreement pursuant to the terms of each respective agreement, and various other holders of Class B Common Stock became parties to the Exchange Agreement. On December 28, 2015, M&F TTP Holdings LLC contributed its shares of Class B Common Stock and the corresponding vTv Units to its subsidiary, M&F, which became the successor to M&F TTP Holdings LLC under the Investor Rights Agreement, Exchange Agreement and Tax Receivable Agreement pursuant to the terms of each respective agreement.

Reclassifications

To facilitate comparison of information across periods, certain reclassifications have been made to prior period amounts to conform to the current period’s presentation.

Principles of Consolidation

Subsequent to the IPO and the Reorganization Transactions, vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv LLC, the Company’s principal operating subsidiary, which is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.

The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its consolidated financial statements. Various holders own non-voting interests in vTv LLC, representing a 70.5% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 29.5% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional vTv Units or should the holders of vTv Units decide to exchange such units (together with shares of Class B Common Stock) for shares of Class A Common Stock (or cash) pursuant to the Exchange Agreement. vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the IPO in 2015, its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016 and its entrance into the letter agreement with MacAndrews and Forbes Group LLC (the “Letter Agreement”) in December 2017. vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC outside of its obligations pertaining to the Loan Agreement as a co-borrower. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. The creditors of vTv LLC do not have any recourse to the general credit of vTv Therapeutics Inc. except as allowed under the provisions of the Loan Agreement. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.

As the Reorganization Transactions were considered to be among entities under common control, the Consolidated Financial Statements for periods prior to the IPO and Reorganization Transactions have been adjusted to combine the historical financial statements of TTP and HPP (which were previously separate entities) for presentation purposes. The historical combined financial statements of these entities include assets and liabilities not transferred to the Company as part of the Reorganization Transactions as discussed above.

Going Concern and Liquidity

To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of the Company’s drug candidates will require additional financing. From its inception through December 31, 2017, the Company has funded its operations primarily through a combination of private placements of preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of December 31, 2017, the Company had an accumulated deficit of $279.1 million and has generated net losses in each year of its existence. The Company’s currently available sources of liquidity include the Company’s cash and cash equivalents balance as of December 31, 2017 of $11.8 million, the $7.2 million upfront payment receivable from our Huadong License Agreement, net of applicable foreign withholding taxes, and the $10.0 million of funds available under the Letter Agreement, which management believes will allow the Company to continue its operations and activities for a period of less than twelve months from the issuance of these Consolidated Financial Statements.

Based on the Company’s current operating plan, management believes that the current cash and cash equivalents will allow the Company to meet its liquidity requirements through the receipt of top-line results for Subpart A of its STEADFAST Study which we anticipate receiving in April 2018. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition to available cash and cash equivalents, the Company is seeking possible partnering opportunities for its GKA, GLP-1r and other drug candidates which it believes may provide additional cash for use in its operations and the continuation of the clinical trials for its drug candidates. The Company may also pursue other sources of financing to provide flexibility to its operating plan. The timing and availability of such financing is not yet known.

The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2: Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A Common Stock, the fair value of the Class B Common Stock, the useful lives of property and equipment, the fair value of the Company’s membership units, the fair value of redeemable preferred units, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.

Accounts receivable as of December 31, 2017, consisted entirely of the upfront payment due in connection with the License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”) which was fully received in January 2018. There were no accounts receivable at December 31, 2016.

Four customers represented 100% of the revenue earned during the year ended December 31, 2017. Two customers represented 100% of the revenue earned during the years ended December 31, 2016 and 2015.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted Cash and Cash Equivalents

Restricted cash and cash equivalents as of December 31, 2017 was $0.2 million. This amount has been received through a research, development and commercialization agreement with JDRF International (“JDRF”) (the “JDRF Agreement”) but has not yet been utilized to fund the development activities required under the JDRF Agreement. Restricted cash and cash equivalents, long-term as of December 31, 2017 was $2.5 million. This amount relates to the minimum balance that the Company must maintain in a deposit account pledged to secure the Loan Agreement and subject to an account control agreement pursuant to the Loan Agreement, as amended. There were no balances of restricted cash and cash equivalents as of December 31, 2016.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets as of December 31, 2017 and 2016 that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows (in thousands):

	2017		2016
Cash and cash equivalents	$	11,758	$	51,505
Restricted cash and cash equivalents		162		—
Restricted cash and cash equivalents, long-term		2,500		—
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$	14,420	$	51,505

Collaboration Revenue and Accounts Receivable

The majority of the Company’s collaboration revenue and accounts receivable relates to its agreements to license certain of its potential drug products for development. See Note 3 for further discussion of the Company’s collaboration agreements.

Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables.

Property and Equipment and other Long-lived Assets

The Company records property and equipment at cost less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to ten years. Leasehold improvements are depreciated over the shorter of the useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.

The estimated useful lives of property and equipment are as follows:

Asset Category	Useful Life (in years)
Laboratory equipment	7
Computers and hardware	3-5
Furniture and office equipment	3-7
Software	3
Leasehold improvements	Shorter of useful life or remaining term of lease

The Company periodically assesses it property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. There were no assets held for sale at December 31, 2017 or 2016.

Investments

In connection with the Reneo License Agreement, the Company received common stock and certain participation rights representing a minority equity interest in Reneo that is classified as a long-term investment in the Company’s Consolidated Balance Sheet as of December 31, 2017. Upon acquisition, on December 21, 2017, this investment was recognized at its fair value of $2.5 million. This investment is accounted for under the cost method because the Company owns less than 20% of the voting equity and does not have the ability to exercise significant influence over Reneo. The Company monitors this investment for impairment and will make appropriate reductions to its carrying value when necessary. No indicators of impairment have occurred since its acquisition. The Company did not hold any such investments as of December 31, 2016.

Revenue Recognition

The Company uses the revenue recognition guidance established by ASC Topic 605, “Revenue Recognition.” The Company recognizes revenue when 1) persuasive evidence of an arrangement exists; 2) the service has been provided to the customer; 3) collection of the fee is reasonably assured; and 4) the amount of the fee to be paid by the customer is fixed or determinable. In determining the accounting for collaboration and alliance agreements, the Company follows the provisions of ASC Topic 605, Subtopic 25, “Multiple-Element Arrangements” (“ASC 605-25”) and ASC 808 (“Collaborative Arrangements”). ASC 605-25 provides guidance on whether an arrangement that involves multiple revenue-generating activities or deliverables should be divided into separate units of accounting for revenue recognition purposes and, if division is required, how the arrangement consideration should be allocated among the separate units of accounting. If a deliverable has value on a stand-alone basis, the Company treats the deliverable as a separate unit of accounting. If the arrangement constitutes separate units of accounting according to the separation criteria of ASC 605-25, the consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria is applied to each unit. The Company determines how to allocate amounts received under agreements among the separate units based on the respective selling price of each unit. If the arrangement constitutes a single unit of accounting, the revenue recognition policy must be determined for the entire arrangement and the consideration received is recognized over the period of inception through the date the last deliverable within the single unit of accounting is expected to be delivered.

Collaboration research and development revenue is earned and recognized as research is performed and related expenses are incurred. Non-refundable upfront fees are recorded as deferred revenue and recognized into revenue as license fees and milestones from collaborations on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, it recognizes non-refundable upfront fees into revenue ratably over the period during which the product deliverable is provided to the customer.

Revenue for non-refundable payments based on the achievement of milestone events under collaborative arrangements is recognized in accordance with ASC Topic 605, Subtopic 28, “Milestone Method” (“ASC 605-28”). Milestone events under the Company’s collaboration agreements may include research, development, regulatory, commercialization, and sales events. Under ASC 605-28, a milestone payment is recognized as revenue when the applicable event is achieved if the event meets the definition of a milestone and the milestone is determined to be substantive. ASC 605-28 defines a milestone event as an event having all of the following characteristics: (1) substantive uncertainty regarding achievement of the milestone event exists at the inception of the arrangement; (2) the event can only be achieved based, in whole or in part, on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (3) if achieved, the event will result in additional payment due to the Company. The Company also treats events that can only be achieved based, in whole or in part, on either a third party’s performance or a specific outcome resulting from a third party’s performance as milestone events if the criteria of ASC 605-28 are otherwise satisfied.

Research and development costs that are reimbursable under collaboration agreements are recorded in accordance with ASC Topic 605, Subtopic 45, “Principal-Agent Considerations.” Amounts reimbursed under a cost-sharing arrangement are reflected as reductions of research and development expense.

Fair Value of Financial Instruments

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

•

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

•

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

•

Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Research and Development

Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.

The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.

The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Consolidated Statements of Operations as the Company receives the related goods or services.

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations.

Income Taxes

In connection with the IPO, vTv Therapeutics Inc. was formed. From August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30, 2015, TTP and HPP were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level.

As a result of the Reorganization Transactions, vTv Therapeutics Inc. acquired vTv Units and is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC.

The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense.

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs.

The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.

The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s Consolidated Statement of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented.

Redeemable Convertible Preferred Units and Noncontrolling Interest

The Company initially recorded the redeemable convertible preferred units of the Predecessors at their fair values at issuance, net of issuance costs. All of the redeemable convertible preferred units were presented outside of permanent members’ deficit as the units were redeemable at holders’ option at the greater of (a) such series’ liquidation value (i.e., the original cost for each unit of such series (as adjusted for any unit split, unit dividend or other similar events)) plus all declared and unpaid distributions on such series and (b) such series’ fair market value (plus all declared but unpaid distributions on such series). The Company’s policy is to record changes in the redemption value of the redeemable convertible preferred units immediately as they occur and adjust the carrying value to equal the redemption value at each reporting period.

Similarly, the Company records the redeemable noncontrolling interest represented by the vTv Units and the Class B Common stock at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date.

See discussion and additional detail of the redeemable noncontrolling interest at Note 10.

Segment and Geographic Information

Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment.

Share-Based Compensation

Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and compensation expense is recognized for those awards earned over the service period. The grant date fair value of stock option awards is estimated using the Black-Scholes option pricing formula. Due to the lack of sufficient historical trading information with respect to its own shares, the Company estimates expected volatility based on the volatility of its own stock as well as a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. Due to a lack of historical exercise data, the Company estimates the expected life of its outstanding stock options using the simplified method specified under Staff Accounting Bulletin Topic 14.D.2. The fair value of restricted stock units (“RSU”) grants are based on the market value of the Class A Common Stock on the date of grant. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee turnover rates.

Comprehensive Income

The Company does not have any components of other comprehensive income recorded within its Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Consolidated Financial Statements.

Recently Issued Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue From Contracts With Customers”, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The ASU is based on the core principle that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. In addition, in March, April, and May 2016, the FASB issued final amendments to clarify the implementation guidance for principal versus agent considerations, identifying performance obligations and the accounting for licenses of intellectual property, and narrow-scope improvements and practical expedients, respectively. This ASU is effective for fiscal years beginning after December 15, 2017 including interim periods within that reporting period. The Company plans to adopt this guidance using the modified retrospective transition method. The Company has evaluated the impact of the adoption of this statement and does not expect it to have a material impact on its Consolidated Financial Statements. The adoption will, however, require certain incremental costs of obtaining its contracts with customers to be recorded as assets upon adoption and be amortized over the related recognition period.

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, which amends ASC 825-10, Financial Instruments – Overall. This ASU amends various aspects of the recognition, measurement, presentation and disclosure of financial instruments. This ASU is effective for fiscal years beginning after December 31, 2017, including interim periods within those fiscal years. The Company plans to elect to use the measurement alternative, defined as cost, less impairments, adjusted by observable price changes. The adoption of this guidance will increase the volatility of the Company’s other income (loss) as a result of the remeasurement of its financial instruments upon the occurrence of observable price changes and impairments.

In February 2016, the FASB issued ASU No. 2016-02, “Lease (Topic 842)” (“ASU 2016-02”), which increases transparency and comparability among companies accounting for lease transactions. The most significant change of this update will require the recognition by a lessee of lease assets and liabilities on its balance sheet for operating lease arrangements with lease terms greater than 12 months. This update will require a modified retrospective application which includes a number of optional practical expedients related to the identification and classification of leases commenced before the effective date. This ASU is effective for fiscal years and interim periods within those fiscal years, beginning after December 18, 2018. The adoption of this guidance will result in the recognition of additional assets and liabilities related to the Company’s operating leases within its Consolidated Balance Sheets.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this guidance in the first quarter of fiscal 2017 on a prospective basis and will continue to estimate forfeitures of outstanding awards throughout the requisite service period. The adoption of this guidance did not have a material impact on the Company’s Consolidated Financial Statements.

In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash” (“ASU 2016-18”), which clarifies the classification and presentation of changes in restricted cash on the statement of cash flows. The update requires beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include cash and cash equivalents as well as restricted cash and restricted cash equivalents. This ASU is effective for fiscal years beginning after December 15, 2017, including interim reporting periods within those fiscal years. The Company elected to early adopt this guidance in the fourth quarter of 2017. The adoption of the guidance changed the presentation of restricted cash and restricted cash equivalents within its Consolidated Statements of Cash Flows but did not have a material impact on the Company’s Consolidated Financial Statements.

In May 2017, the FASB issued ASU No. 2017-09, “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), which clarifies the changes to terms or conditions of a share-based payment award that require an entity to apply modification accounting. ASU 2017-09 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. Early application is permitted and prospective application is required. The Company does not expect that the adoption of this guidance will have a material impact on the Company's Consolidated Financial Statements.

Collaboration Agreements	12 Months Ended
Collaboration Agreements	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaboration Agreements	Note 3: Collaboration Agreements Reneo License Agreement On December 21, 2017, the Company entered into a License Agreement with Reneo Pharmaceuticals, Inc. (“Reneo”) (the “Reneo License Agreement”), under which Reneo obtained an exclusive, worldwide, sublicensable license to develop and commercialize the Company’s peroxisome proliferation activated receptor delta (PPAR-δ) agonist program, including the compound HPP593, for therapeutic, prophylactic or diagnostic application in humans. Under the terms of the Reneo License Agreement, Reneo paid the Company an upfront cash payment of $3.0 million. The Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $94.5 million. In addition, Reneo is obligated to pay the Company royalty payments at mid-single to low-double digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company has also received common stock and certain participation rights representing a minority equity interest in Reneo. Pursuant to the terms of the Reneo License Agreement, the Company is required to provide technology transfer services for a defined period after the effective date. In accordance with ASC 605-25, the Company identified all of the obligations at the inception of the Reneo License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single unit of accounting because they were not viewed to have standalone value. The Company also determined that there was no discernable pattern in which the technology services would be provided during the transfer services period. As such, the Company determined that the straight-line method would be used to recognize revenue over the transfer service period of 18 months and $0.1 million of revenue was recorded during the year ended December 31, 2017. The development, regulatory and sales milestones represent non-refundable amounts that would be paid by Reneo to the Company if certain milestones are achieved in the future. The Company has elected to apply the guidance in ASC 605-28 to these milestones. These milestones, if achieved, are considered substantive as they relate solely to past performance and are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of the Company’s performance. However, there can be no assurance that Reneo will achieve the milestones or that the Company will receive the related revenue. Huadong License Agreement On December 21, 2017, the Company entered into a License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. Under the terms of the Huadong License Agreement, Huadong will pay the Company an initial license fee of $8.0 million and potential development and regulatory milestone payments totaling up to $25.0 million, with an additional potential regulatory milestone of $20.0 million if Huadong receives regulatory approval for a central nervous system indication. In addition, the Company is eligible for an additional $50.0 million in potential sales-based milestones, as well as royalty payments ranging from low-single to low-double digit rates, based on tiered sales of licensed products. Under the Huadong License Agreement, the Company is also responsible for conducting a Phase 2 multi-region clinical trial (the “Phase 2 MRCT”) including sites in both the United States and Huadong License Territory for the purpose of assessing the safety and efficacy of TTP273 in patients with type 2 diabetes. The Phase 2 MRCT will be designed to satisfy the requirements of the China Food and Drug Administration necessary in order for Huadong to begin a Phase 3 clinical trial in China. The Company will also be responsible for contributing up to $3.0 million in connection with the Phase 2 MRCT In accordance with ASC 605-25, the Company identified all of the obligations at the inception of the Huadong License Agreement. The significant obligations were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date (iii) the obligation to sponsor and conduct the Phase 2 MRCT, (iv) the Company’s obligation to participate on a joint development committee, and (v) other obligations considered to be de minimis in nature. The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined unit of accounting because they were not viewed to have separate standalone value. The portion of the upfront payment allocated to this combined unit of accounting was estimated to be $6.9 million. The Company also determined that there was no discernable pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company determined that the straight-line method would be used to recognize revenue for this unit of accounting over the transfer service period of 18 months. For the year ended December 31, 2017, $0.1 million of revenue has been recognized related to this combined unit of accounting. The Company also determined that the obligation to sponsor and conduct a portion of the Phase 2 MRCT should be treated as a separate unit of accounting. A portion of the total consideration received under the Huadong License Agreement was allocated to this unit of accounting based on its estimated fair value. This amount was deferred as of December 31, 2017 and revenue will be recognized using the proportional performance model over the period during which the Company conducts the Phase 2 MRCT trial. No revenue for this unit of accounting has been recognized during the year ended December 31, 2017. The Company also determined that the obligation to participate in the joint development committee (the “JDC”) to oversee the development of products and the Phase 2 MRCT in accordance with the development plan should be treated as a separate unit of accounting. A portion of the total consideration received under the Huadong License Agreement was allocated to this unit of accounting based on its estimated fair value. This amount was deferred as of December 31, 2017 and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. No revenue for this unit of accounting has been recognized during the year ended December 31, 2017. The development, regulatory and sales milestones represent non-refundable amounts that would be paid by Huadong to the Company if certain milestones are achieved in the future. The Company has elected to apply the guidance in ASC 605-28 to these milestones. These milestones, if achieved are substantive as they relate solely to past performance and are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of the Company’s performance. However, there can be no assurance that Huadong will achieve the milestones or that the Company will receive the related payments. JDRF Agreement In August 2017, the Company entered into the JDRF Agreement to support the funding of the simplici-T1 Study, an adaptive Phase 1b/2 study to explore the effects of TTP399 in type 1 diabetics. We initiated this study in the fourth quarter of 2017. According to the terms of the JDRF Agreement, JDRF will provide research funding of up to $3.0 million based on the achievement of research and development milestones, with the total funding provided by JDRF not to exceed approximately one-half of the total cost of the project. Additionally, the Company has the obligation to make certain milestone payments to JDRF upon the commercialization, licensing, sale or transfer of TTP399 as a treatment for type 1 diabetes. Payments that the Company receives from JDRF under this agreement will be recorded as restricted cash and current liabilities, and recognized as an offset to research and development expense, based on the progress of the project, and only to the extent that the restricted cash is utilized to fund such development activities. As of December 31, 2017, the Company had received funding under this agreement of $0.3 million, and research and development costs were offset by $0.2 million. As of December 31, 2017, the Company has recognized restricted cash of $0.2 million related to this agreement. Calithera License Agreement In March 2015, the Company entered into the Calithera License Agreement under which Calithera obtained an exclusive, worldwide sublicenseable license to develop and commercialize certain of our hexokinase II inhibitors for any therapeutic, prophylactic, preventative or diagnostic use. Under the terms of the Calithera License Agreement, Calithera paid the Company an initial license fee of $0.6 million and a total of $0.3 million for employees of the Company to assist with the development of additional hexokinase inhibitors. This agreement was terminated, at the option of Calithera, effective December 21, 2017.

Share-Based Compensation

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-Based Compensation

Note 4: Share-Based Compensation

In conjunction with the IPO, the Board of Directors and sole stockholder adopted a long-term equity incentive plan, the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan (the “Plan”). The Plan provides for the grant of stock options, restricted stock, restricted stock units and other awards based on our Class A Common Stock to management, other key employees, consultants and non-employee directors on terms and subject to conditions as established by our Compensation Committee. In settlement of its obligations under this plan, the Company will issue new shares of Class A Common Stock. The maximum number of shares of the Company’s Class A Common Stock that has been approved and may be subject to awards under the Plan is 3.25 million, subject to adjustment in accordance with terms of the Plan.

The Company has issued non-qualified stock option awards and restricted stock units to certain employees, consultants and non-employee directors of the Company. These awards generally vest ratably over a three year period and the option awards expire after a term of ten years from the date of grant. For the years ended December 31, 2017, 2016 and 2015, the Company recognized $3.6 million, $2.6 million and $0.9 million of compensation expense related to share-based awards, respectively. Given that the Company has established a full valuation allowance against its deferred tax assets, the Company has recognized no tax benefit related to these awards. As of December 31, 2017, the Company had total unrecognized stock-based compensation expense of approximately $4.3 million, which is expected to be recognized on a straight-line basis over a weighted average period of 1.6 years. The weighted average grant date fair value for all option grants during the years ended December 31, 2017, 2016 and 2015 was $4.15, $4.05 and $8.15 per option, respectively.

The aggregate intrinsic value of the in-the-money awards outstanding as of December 31, 2017 was $0.3 million, of which an immaterial amount related to vested stock options and $0.2 million related to unvested stock options.

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions during the years ended December 31, 2017, 2016 and 2015:

	For the Year Ended December 31,
	2017		2016		2015
Expected volatility	68.72% - 85.93%		81.57% - 87.23%		83.84% - 88.23%
Expected life of option, in years	5.8 - 6.0		5.0 - 6.0		5.8 - 9.6
Risk-free interest rate	1.87% - 2.24%		1.22% - 1.45%		1.72% - 2.25%
Expected dividend yield		0.00%		0.00%		0.00%

The following table summarizes the activity related to the stock option awards for the year ended December 31, 2017 (in thousands, except per share amounts):

	Number of Shares			Weighted- Average Exercise Price
Awards outstanding at December 31, 2016		1,096,101		$	10.68
Granted		882,000			5.77
Forfeited		(17,369	)		6.95
Awards outstanding at December 31, 2017		1,960,732		$	8.50
Options exercisable at December 31, 2017		716,787		$	10.84
Weighted average remaining contractual term	7.8 Years
Options vested and expected to vest at December 31, 2017		1,906,322		$	8.57
Weighted average remaining contractual term	8.4 Years

The following table summarizes the activity related to the awards of RSUs for the year ended December 31, 2017:

	Number of Shares		Weighted- Average Grant Date Fair Value
Awards outstanding at December 31, 2016		—	$	—
Granted		35,000		5.81
Awards outstanding at December 31, 2017		35,000	$	5.81
RSUs vested and expected to vest at December 31, 2017		34,002	$	5.81

As of December 31, 2017, the Company had total unrecognized stock-based compensation expense for its outstanding RSU awards of approximately $0.2 million, which is expected to be recognized over a weighted-average period of 2.4 years. The aggregate intrinsic value of the RSUs outstanding at December 31, 2017 was $0.2 million.

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):

	2017		2016		2015
Research and development	$	1,485	$	975	$	221
General and administrative		2,160		1,666		638
Total share-based compensation expense	$	3,645	$	2,641	$	859

Property and Equipment

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Property and Equipment

Note 5: Property and Equipment

Property and equipment consists of the following (in thousands):

	December 31,
	2017			2016
Laboratory equipment	$	6,275		$	6,962
Leasehold improvements		1,679			2,358
Computers and hardware		323			292
Software		691			855
Furniture and office equipment		431			431
Total property and equipment		9,399			10,898
Less: accumulated depreciation and amortization		(9,116	)		(10,454	)
Property and equipment, net	$	283		$	444

Depreciation expense, including amounts pertaining to assets held under capital leases, was $0.2 million, $0.3 million and $0.5 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Accounts Payable and Accrued Expenses

Note 6: Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following (in thousands):

	December 31,
	2017		2016
Accounts payable	$	2,269	$	3,060
Accrued development costs		8,586		6,305
Accrued payroll related costs		1,641		1,468
Accrued other		1,405		580
Total	$	13,901	$	11,413

Notes Payable

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Notes Payable

Note 7: Notes Payable

Notes payable consist of the following (in thousands):

	December 31,
	2017			2016
Notes payable under the Loan Agreement	$	20,000		$	12,500
Less: Debt discount		(413	)		(1,442	)
Total notes payable		19,587			11,058
Less: Current portion		(4,271	)		—
Total notes payable, net of current portion	$	15,316		$	11,058

In October 2016, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation and Silicon Valley Bank, under which the Company and vTv LLC borrowed $20.0 million.

Each loan tranche bears interest at a floating rate equal to 10.5% plus the amount by which the one-month LIBOR exceeds 0.5%.

The Company borrowed the first tranche of $12.5 million upon close of the Loan Agreement in October 2016. The first tranche requires only monthly interest payments until May 1, 2018 followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on May 1, 2020. In addition, a final payment for the first tranche loan equal to $0.8 million will be due on May 1, 2020, or such earlier date specified in the Loan Agreement. The Company borrowed the second tranche of $7.5 million in March 2017. The second tranche requires only monthly interest payments until October 1, 2018, followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on October 1, 2020. In addition, a final payment for the second tranche loan equal to $0.5 million will be due on October 1, 2020, or such earlier date specified in the Loan Agreement. The availability of the third tranche of $5.0 million expired unused on June 30, 2017.

If the Company repays all or a portion of the loan prior to the applicable maturity date, it will pay the Lenders a prepayment penalty fee, based on a percentage of the then outstanding principal balance equal to 4.0% during the first 18 months following the funding of the second tranche and 2.0% thereafter.

In connection with the Loan Agreement, the Company has issued to the Lenders warrants to purchase shares of the Company’s Class A Common Stock (the “Warrants”). On October 28, 2016, the Company issued Warrants to purchase 152,580 shares of its Class A Common Stock at a per share exercise price of $6.39 per share, which aggregate exercise price represents 6.0% of the principal amount borrowed under the first tranche of the Loan Agreement and 3.0% of the principal amount available under the second tranche of the Loan Agreement. On March 24, 2017, in connection with the funding of the second tranche, the Company issued Warrants to purchase 38,006 shares of its Class A Common Stock at a per share exercise price of $5.92 per share, which aggregate exercise price represents 3.0% of the principal amount of the second tranche of the Loan Agreement. In each instance, the Warrants have an exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants. The Warrants will expire seven years from their date of issuance.

The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. Subject to certain conditions related to the Company’s Phase 3 clinical trial of azeliragon, the Company may be required to grant a security interest in its intellectual property. The Company has agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions.

The Loan Agreement includes customary affirmative and restrictive covenants, including, but not limited to, restrictions on the payment of dividends or other equity distributions and the incurrence of debt or liens upon the assets of the Company or its subsidiaries. The Loan Agreement does not contain any financial maintenance covenants other than a requirement to maintain a minimum cash balance of not less than $2.5 million in a deposit account pledged to secure the Loan Agreement and subject to an account control agreement. The minimum cash balance covenant was included as part of an amendment to the Loan Agreement in connection with our entry into the Huadong License Agreement in December 2017. The Loan Agreement includes customary events of default, including payment defaults, covenant defaults, and material adverse change default. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% will be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

The Company incurred $0.7 million of costs in connection with the Loan Agreement in the year ended December 31, 2016. These costs, along with the allocated fair value of the Warrants issued of $0.9 million, were treated as a debt discount, and are offset against the carrying value of the notes payable in the Company’s Consolidated Balance Sheet as of December 31, 2017 and 2016. These costs will be recognized as interest expense over the term of the first tranche using the effective interest method. The final payment for the first and second loan tranches of $0.8 million and $0.5 million, respectively, will be accrued as additional interest expense, using the effective interest method, over the term of the relevant tranche.

The Company recorded interest expense related to the Loan Agreement of $3.1 million and $0.4 million for the years ended December 31, 2017 and 2016, respectively. The annual effective interest rate on the note payable, including the amortization of the debt discounts and accretion of the final payments, is 17.7%.

Principal payments due under the terms of the Loan Agreement are as follows (in thousands):

2018	$	4,271
2019		10,000
2020		5,729
2021		—
2022		—
Total	$	20,000

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8: Commitments and Contingencies

Legal Matters

From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.

Columbia University Agreement

In May 2015, the Company entered into a worldwide exclusive agreement with Columbia University (“Columbia”) to license certain intellectual property from Columbia. Under the agreement, the Company is obligated to pay to Columbia (1) an annual fee of $0.1 million from 2015 through 2021, (2) a potential regulatory milestone payment of $0.8 million and (3) potential royalty payments at a single digit royalty rate based on net sales of licensed products as defined in the agreement.

Novo Nordisk

In February 2007, the Company entered into an Agreement Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo License Agreement”) whereby we obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as TTP399. Under the terms of the Novo License Agreement, the Company has additional potential developmental and regulatory milestone payments totaling up to $115.0 million for approval of a product. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.

Huadong License Agreement

Under the terms of the Huadong License Agreement, vTv LLC is responsible for sponsoring the Phase 2 MRCT including sites in both US and the Huadong License Territory for the purpose of assessing the safety and efficacy of TTP273 in patients with type 2 diabetes. The Phase 2 MRCT will be designed to satisfy the requirements of the China Food and Drug Administration necessary in order for Huadong to begin a Phase 3 clinical trial in China. vTv LLC will be responsible for contributing up to $3.0 million in connection with the Phase 2 MRCT.

Lease Agreements

The Company leases various equipment and facilities under operating leases expiring at various dates through 2019. Rent expense for non-cancelable operating leases was $0.5 million, $0.6 million and $0.6 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Future minimum lease payments under non-cancelable operating leases as of December 31, 2017 were as follows (in thousands):

Year Ending December 31,	Operating Leases
2018	$	365
2019		371
2020		—
2021		—
2022		—
Total	$	736

The Company has recognized an asset retirement obligation for an obligation in its facility lease that requires the Company to return the property to the same or similar condition at the end of the lease as existed when the Company began using the facility. Although the lease termination date is currently in 2019, the Company may be able to renegotiate the lease to extend its terms. Asset retirement obligations recorded as a component of other noncurrent liabilities in the Consolidated Balance Sheets were $0.2 million at both December 31, 2017 and 2016. An immaterial amount of accretion and depreciation expense was recognized in the years ended December 31, 2017 and 2016.

Stockholders' Equity

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Stockholders' Equity

Note 9: Stockholders’ Equity

On July 29, 2015, the Company amended and restated its certificate of incorporation to authorize 100,000,000 shares of Class A Common Stock, 100,000,000 shares of Class B Common Stock and 50,000,000 shares of preferred stock, par value $0.01 per share.

Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval. The holders of Class A Common Stock and Class B Common Stock will vote together as a single class on all matters submitted to stockholders for their vote or approval, except with respect to the amendment of certain provisions of the Company’s amended and restated certificate of incorporation that would alter or change the powers, preferences or special rights of the Class B Common Stock so as to affect them adversely, which amendments must be approved by a majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class, or as otherwise required by applicable law. The voting power of the outstanding Class B Common Stock (expressed as a percentage of the total voting power of all common stock) will be equal to the percentage of vTv Units not held by the Company. Holders of Class B Common Stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company.

Equity Financing

On December 5, 2017, the Company entered into the Letter Agreement with MacAndrews, a related party. Under the Letter Agreement, until December 5, 2018, the Company has the right to sell to MacAndrews shares of its Class A Common Stock at a price equal to $4.38 per share, and MacAndrews has the right (exercisable up to three times) to require the Company to sell to it shares of its Class A Common Stock at the same price. An aggregate of $10.0 million worth of Class A Common Stock may be sold under the Letter Agreement (whether at the Company’s or MacAndrews’ option). In addition, in connection with the Letter Agreement, the Company also issued MacAndrews warrants (the “Consideration Warrants”) to purchase 198,267 shares of the its Class A Common Stock, exercisable at a price of $5.04 per share (which is 115% of the option price under the Letter Agreement), exercisable until December 5, 2024.

The Consideration Warrants were recorded as warrant liability, related party within the Company’s Consolidated Balance Sheet as of December 31, 2017 based on their fair value. The issuance of the Consideration Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. During the year ended December 31, 2017 the Company recognized an expense of $0.2 million related to the change in fair value of the Consideration Warrants. This expense was recognized as a component of other expense, related party in the Consolidated Statements of Operations.

Fair value of the Consideration Warrants was calculated as of December 5, 2017 using the methods described in Note 17 using the following assumptions:

Expected volatility		90.0%
Expected life of option, in years		7.0
Risk-free interest rate		2.8%
Expected dividend yield		0.00%

Loan Agreement Warrants

On October 28, 2016, the Company entered into the Loan Agreement as discussed in Note 7. In connection with the Loan Agreement, the Company issued to the Lenders Warrants to purchase a total of 152,580 shares of the Company’s Class A Common Stock at an exercise price of $6.39 per share. Additionally, upon funding of the second tranche on March 24, 2017, the Company issued Warrants to purchase 38,006 shares of its Class A Common Stock at a per share exercise price of $5.92 per share, which aggregate exercise price represents 3.0% of the amount available under the second tranche of the Loan Agreement. In each instance, the Warrants have an exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants. The Warrants will expire seven years from their date of issuance.

The Warrants issued with a determinable number of shares and exercise price were recorded as a component of additional paid-in capital within the Company’s Consolidated Balance Sheet as of December 31, 2016 based on their relative fair value. The Warrants issued for a variable number of shares were recorded as a component of other liabilities within the Consolidated Balance Sheet as of December 31, 2016. This related liability was adjusted to its fair value on a periodic basis until the associated warrants qualified for equity classification upon the funding of the second tranche of the Loan Agreement on March 24, 2017. For the years ended December 31, 2017 and 2016, the Company recognized additional interest expense within the Consolidated Statement of Operations of a de minimis amount related to the adjustment of the Warrants to their fair value.

Fair value of the Warrants was calculated as of October 28, 2016 using the methods described in Note 17 using the following assumptions:

Expected volatility		82.54%
Expected life of option, in years		7.0
Risk-free interest rate		1.63%
Expected dividend yield		0.00%

Redeemable Noncontrolling Interest	12 Months Ended
Redeemable Noncontrolling Interest	Dec. 31, 2017
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interest	Note 10: Redeemable Noncontrolling Interest The Company is subject to the Exchange Agreement with respect to the vTv Units representing the outstanding 70.5% noncontrolling interest in vTv LLC (see Note 1). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B Common Stock for (i) shares of Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20 day volume weighted average price of the Class A Common Stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December 31, 2017 and 2016, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $131.4 million and $122.5 million, respectively.

Related-Party Transactions	12 Months Ended
Related-Party Transactions	Dec. 31, 2017
Related Party Transactions [Abstract]
Related-Party Transactions	Note 11: Related-Party Transactions PharmaCore, Inc. Prior to its acquisition by Cambrex Corporation in October 2016, certain controlling shareholders of the Company also controlled PharmaCore, Inc. (“PharmaCore”) and PharmaCore was therefore considered to be a related party. The Company purchased chemistry and Good Manufacturing Practices manufacturing services from PharmaCore. Total purchases from PharmaCore, while it was considered to be a related party were $0.8 million and $2.3 million for the years ended December 31, 2016 and 2015, respectively. On April 17, 2007, the Company’s Board of Directors approved $2.0 million of subordinated financing to be provided to PharmaCore. Advances were made and interest accrued before the Company entered into the Subordinated Promissory Note agreement (the “Note Agreement”) with PharmaCore on June 9, 2008. The Note Agreement was amended on April 23, 2010 to provide an additional $2.9 million of subordinated financing, with the same terms as the original note. The Note Agreement had a nine-year term, a fixed interest rate of 8.25% per annum, with maturity of June 1, 2017. No payments were required through December 31, 2014 with accrued interest capitalized into the principal balance. Thereafter, interest was to be paid quarterly. As part of the agreement, the Company received a warrant, exercisable for up to ten years, to purchase 370,370 common units of PharmaCore at an exercise price of $0.54 per unit. During the year ended December 31, 2015, the Company recorded interest income of $0.4 million related to this financing. This receivable balance was not contributed to the Company as part of the Reorganization Transactions and, as such, no interest income was recognized during the year ended December 31, 2017 or 2016. During the year ended December 31, 2015, the Company recognized bad debt expense of $0.4 million for this Note Agreement due to the uncertainty of the receivable’s collectability. MacAndrews & Forbes Incorporated Subsequent to the Reorganization Transactions (Note 1) subsidiaries of MacAndrews & Forbes Incorporated (collectively “MacAndrews”) indirectly control 23,084,267 shares of Class B Common Stock. Further, as of December 31, 2017, MacAndrews holds 2,615,666 shares of the Company’s Class A Common Stock. As a result, MacAndrews’ holdings represent approximately 78.3% of the combined voting power of the Company’s outstanding common stock. The Company has entered into several agreements with MacAndrews or its affiliates as part of the Reorganization Transactions as further detailed below and in Notes 1 and 9. Equity Financing In December 2017, the Company entered into the Letter Agreement with MacAndrews. Under the Letter Agreement, until December 5, 2018, the Company has the right to sell to MacAndrews shares of its Class A Common Stock at a price equal to $4.38 per share, and MacAndrews has the right (exercisable up to three times) to require the Company to sell to it shares of Class A Common Stock at the same price. An aggregate of $10.0 million worth of Class A Common Stock may be sold under the Letter Agreement (whether at the Company’s or MacAndrews’ option). In addition, in connection with the Letter Agreement, the Company also issued MacAndrews warrants to purchase 198,267 shares of the Company’s Class A Common Stock at a price of $5.04 per share, exercisable until December 5, 2024. Exchange Agreement Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for (i) shares of the Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A Common Stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire Board of Directors. As of December 31, 2017, MacAndrews has not exchanged any shares under the provisions of this agreement. Tax Receivable Agreement The Tax Receivable Agreement among the Company, M&F and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability nor has it made any payments pursuant to the Tax Receivable Agreement as of December 31, 2017. Investor Rights Agreement The Company is party to the Investor Rights Agreement with M&F, as a successor in interest to vTv Therapeutics Holdings. The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration rights with respect to its shares of Class A Common Stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A Common Stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. Letter Agreement for Reimbursement of Fees and Expenses The Company entered into an agreement with MacAndrews & Forbes Group LLC (“M&F Group”) in which it agreed to reimburse M&F Group or its affiliates for certain out of pocket fees and expenses advanced by M&F Group in connection with the IPO. During the year ended December 31, 2015, the Company remitted payments to M&F Group or its affiliates of $1.3 million for such costs.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

Note 13: Income Taxes

From August 1, 2015, vTv Therapeutics Inc. has been subject to U.S. federal income taxes as well as state taxes. Prior to July 30, 2015, TTP and HPP were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level. The Company recorded an income tax provision of $0.8 million for the year ended December 31, 2017 representing foreign withholding taxes incurred in connection with the Huadong License Agreement. The Company did not record an income tax provision for the years ended December 31, 2016 and 2015.

As discussed in Note 1, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of December 31, 2017.

On December 22, 2017, the US government enacted comprehensive tax reform commonly referred to as the Tax Cuts and Jobs Act (“TCJA”). Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. Among other things, the TCJA (1) reduces the US statutory corporate income tax rate from 35% to 21% effective January 1, 2018, (2) eliminates the corporate alternative minimum tax, (3) eliminates the Section 199 deduction, and (4) changes rules related to uses and limitations of net operating loss carryforwards beginning after December 31, 2017.

The SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides guidance on accounting for the tax effects of TCJA. SAB 118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting under ASC 740. To the extent that a company’s accounting for certain income tax effects of the TCJA is incomplete but is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements.

The TCJA reduces the corporate tax rate to 21% effective January 1, 2018. We have recorded a provisional decrease in our deferred tax assets of $5.8 million with a corresponding adjustment to the valuation allowance for the year ended December 31, 2017. While we are able to make a reasonable estimate of the impact of the reduction in the corporate rate, it may be affected by other analyses related to the TCJA. The Company will continue to assess and refine, as necessary, its accounting for the TCJA as additional guidance and interpretation is provided.

A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):

	December 31,
	2017			2016			2015
U.S. statutory tax benefit	$	(18,846	)	$	(19,374	)	$	(14,387	)
Partnership income (federal) not subject to tax to the Company		13,475			13,651			12,502
Foreign withholding tax		800			—			—
State taxes (net of federal benefit)		55			—			—
Impact of the Tax Act		5,847			—			—
Change in valuation allowance		(531	)		5,723			1,885
Provision for income taxes	$	800		$	—		$	—
Effective income tax rate		-1.5	%		0.0	%		0.0	%

Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):

	December 31,
	2017			2016
Deferred tax assets:
Net operating loss carryforwards	$	9,023		$	8,189
Share-based compensation		—			3
Investment in partnerships		470			1,844
Charitable contributions		11			—
Total deferred tax assets		9,504			10,036
Valuation allowance		(9,504	)		(10,036	)
Net deferred tax assets	$	—		$	—

The Company assesses the available positive evidence and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of existing deferred tax assets. A significant piece of objective negative evidence evaluated was the Company’s recent operating losses. Such objective evidence limits the ability to consider other subjective evidence, such as forecasts of profitability. On the basis of this evaluation, the Company concluded that its deferred tax assets were not realizable on a more-likely-than-not basis and recorded a full valuation allowance. During the year ended December 31, 2017, the Company’s valuation allowance decreased by $0.5 million.

The Company has federal net operating loss carryforwards of $40.2 million that will be available to offset future taxable income. Such carryforwards expire in 2035 and 2037 if not utilized.

The Company applies applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2017, the Company had no uncertain tax positions. There are no uncertain tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of December 31, 2017.

The Company files U.S. federal, Connecticut, New York, North Carolina and Virginia tax returns. The only open tax years for U.S. federal and the aforementioned states are December 31, 2017, 2016 and 2015.

Net Loss per Share

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Net Loss per Share

Note 14: Net Loss per Share

Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for the years ended December 31, 2017, 2016 and 2015 is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. Loss per share for the year ended December 31, 2015 includes the losses recognized both prior and subsequent to the IPO and Reorganization Transactions.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A Common Stock is as follows (amounts in thousands, except per share amounts):

	Year Ended December 31,
	2017			2016			2015
Numerator:
Net loss	$	(54,647	)	$	(55,353	)	$	(41,107	)
Less: Net loss attributable to noncontrolling interests		(38,503	)		(39,001	)		(13,609	)
Net loss attributable to vTv Therapeutics Inc., basic and diluted	$	(16,144	)	$	(16,352	)	$	(27,498	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		9,693,254			9,545,527			8,276,520
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(1.67	)	$	(1.71	)	$	(3.32	)

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:

	Year Ended December 31,
	2017		2016		2015
Class B Common Stock ⁽¹⁾		23,119,246		23,119,246		23,655,814
Common stock options granted under the Plan		1,960,732		1,096,101		971,934
Restricted stock units		35,000		—		—
Common stock options granted under the Letter Agreement		2,283,105		—		—
Common stock warrants		388,853		152,580		—
Total		27,786,936		24,367,927		24,627,748

(1)

Shares of Class B Common Stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B Common Stock under the two-class method has not been provided. Each share of Class B Common Stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A Common Stock.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Data [Abstract]

Quarterly Financial Data (Unaudited)

Note 15: Quarterly Financial Data (Unaudited)

The following interim financial information presents our 2017 and 2016 results of operations on a quarterly basis (in thousands, except per share amounts):

	2017
	March 31			June 30			September 30			December 31
Revenues	$	30		$	13		$	15		$	233
Operating loss		(13,754	)		(12,615	)		(11,541	)		(12,772	)
Net loss before noncontrolling interest		(14,286	)		(13,414	)		(12,355	)		(14,592	)
Net loss attributable to vTv Therapeutics Inc.		(4,220	)		(3,963	)		(3,650	)		(4,311	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.44	)	$	(0.41	)	$	(0.38	)	$	(0.44	)

	2016
	March 31			June 30			September 30			December 31
Revenues	$	376		$	182		$	38		$	38
Operating loss		(13,540	)		(14,639	)		(13,528	)		(13,313	)
Net loss before noncontrolling interest		(13,520	)		(14,617	)		(13,505	)		(13,711	)
Net loss attributable to vTv Therapeutics Inc.		(3,852	)		(4,457	)		(3,993	)		(4,050	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.42	)	$	(0.47	)	$	(0.41	)	$	(0.42	)

Predecessor Financial Arrangements	12 Months Ended
Predecessor Financial Arrangements	Dec. 31, 2017
Predecessor Financial Arrangements [Abstract]
Predecessor Financial Arrangements	Note 16: Predecessor Financial Arrangements The Reorganization Transactions discussed in Note 1 resulted in certain assets and liabilities of the Predecessors not being contributed to or assumed by the Company. As such, subsequent to the Reorganization Transactions, certain financial instruments and their related interest or fair value adjustments were no longer reflected within the Company’s Consolidated Financial Statements. Such financial instruments included the following: Note receivable from Former Officer - On March 30, 2007, TransTech Pharma, Inc. (“TTP Inc.”) entered into a promissory note (the “2007 Note”) with a former officer and director (“the Former Officer”), pursuant to which TTP Inc. loaned $4.8 million to the Former Officer. Promissory note on land - In June 2008, TTP Inc. entered into a promissory note with a financial institution secured by a deed of trust on land purchased in 2008. Distribution payable - On December 30, 2014, the boards of directors of TTP and HPP authorized a repurchase of units from the Former Officer and certain entities related to the officer (collectively with the Former Officer, the “Former Officer and Related Entities”) of TTP. The terms of the unit repurchase are stipulated in a Letter Agreement (the “Former Officer Agreement”) with the Former Officer and Related Entities. The Former Officer Agreement stipulated that these entities would repurchase all of the TTP and HPP issued and outstanding units owned by the Former Officer and Related Entities, including any warrants and options to purchase common units (collectively, the “Repurchased Units”). In exchange for the Repurchased Units, under the Former Officer Agreement, TTP and HPP agreed to make periodic cash payments to the Former Officer and Related Entities totaling $7.5 million between December 30, 2014 and September 30, 2017. Payments consisted of $2.5 million paid at closing of the agreement on December 30, 2014 and $5.0 million to be paid in eight equal quarterly installments beginning December 31, 2015. Uncommitted advance agreement - On March 28, 2014, TTP, HPP and M&F agreed to exchange all $116.2 million of outstanding principal and interest due to M&F under a Note and Equity Issuance Agreement (including amounts advanced under the initial agreement plus the promissory notes issued in 2013 and amounts advanced following the December 24, 2013 amendment) for 292,722,844 Series F redeemable convertible preferred units of TTP and 155,219,376 Series B redeemable convertible preferred units of HPP. Concurrently on March 28, 2014, TTP and HPP entered into an Uncommitted Advance Agreement with M&F and the Former Officer. As of December 30, 2014, the Former Officer was no longer party to this agreement. Contingent distribution - On December 31, 2014, TTP transferred 100% of its ownership interests in HPCTC to the Former Officer and agreed to make future distributions to the Former Officer (the “Contingent Distributions”). Perpetual securities - On March 28, 2014, TTP entered into a reaffirmation and pledge agreement (“Pledge Agreement”) with the Former Officer and Related Entities. Pursuant to the Pledge Agreement, the Former Officer granted a security interest to TTP in the Pledged Units to secure the Former Officer’s obligations to TTP under the 2007 Note and under the Pledge Agreement. On December 30, 2014, the Pledged Units were exchanged for TTP Perpetual Securities in the principal amount of approximately $6.0 million and HPP Perpetual Securities in the principal amount of approximately $0.5 million (the “Perpetual Securities”). The Perpetual Securities were initially recorded at their initial fair value of $6.6 million. The increase in the fair value of the perpetual securities during the year ended December 31, 2015, prior to the Reorganization Transactions was $0.1 million and is reflected in other income, net in the Consolidated Statements of Operations. Release agreement - On August 28, 2015, vTv Therapeutics Holdings, vTvx Holdings I, vTvx Holdings II, MacAndrews & Forbes Incorporated and M&F entered into a release agreement (the “Release Agreement”) with the Former Officer and Related Entities to settle certain obligations, including the obligation to pay the Contingent Distributions, under the Former Officer Agreement. Under the Release Agreement, vTv Therapeutics Holdings agreed to transfer 1,344,186 shares of Class B Common Stock and the same number of corresponding vTv Units to the Former Officer. Under the Release Agreement and the Former Officer Agreement, the 2007 Note owed by the Former Officer to TTP was also deemed discharged and canceled and the perpetual securities of vTvx Holdings I and vTvx Holdings II having principal amounts of $6.0 million and $0.5 million, respectively, held by the Former Officer, were repurchased by vTvx Holdings I and vTvx Holdings II in exchange therefor. On the same date, under the Exchange Agreement, the Former Officer exchanged those shares of Class B Common Stock and vTv Units for 1,344,186 shares of Class A Common Stock.

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

Note 17: Fair Value of Financial Instruments

The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.

The fair value of the Company’s investment in Reneo at December 21, 2017 was estimated based on the relative value paid by third parties for their equity interest in Reneo through recent capital raising events. The inputs to the calculation of fair value are considered level 3 inputs within the fair value hierarchy.

The fair value of the Company’s notes payable is considered to approximate its carrying value because it bears interest at a variable interest rate.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2017 and 2016 (in thousands):

Balance at December 31, 2017

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability, related party ⁽¹⁾

492

—

492

Total

492

—

492

Balance at December 31, 2016

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability ⁽²⁾

167

—

167

Total

167

—

167

(1)

Fair value determined using an option pricing model based on the Company’s current capitalization. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the yield of U.S. government securities with the same term as the option as of the valuation date.

(2)

Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.

	Changes in Level 3 Instruments for the years ended December 31, 2017, 2016 and 2015
	Balance at January 1		Net Change in fair value included in earnings		Net change in fair value ⁽¹⁾		Purchases / Issuance		Sales / Repurchases			Effect of Reorganization Transaction			Balance at December 31
2017
Warrant liability	$	167	$	—	$	—	$	—	$	(167	)	$	—		$	—
Warrant liability, related party		—		190		—		302		—			—			492
Total	$	167	$	190	$	—	$	302	$	(167	)	$	—		$	492

2016
Warrant liability	$	—	$	—	$	—	$	167	$	—		$	—		$	167
Total	$	—	$	—	$	—	$	167	$	—		$	—		$	167

2015
TTP Redeemable preferred units	$	412,085	$	—	$	66,379	$	—	$	—		$	(478,464	)	$	—
HPP Redeemable preferred units		—		—		—		—		—			—			—
Consideration payable		4,897		—		—		—		—			(4,897	)		—
Note payable		6,594		115		—		—		—			(6,709	)		—
Contingent distribution		26,359		—		695		—		—			(27,054	)		—
Total	$	449,935	$	115	$	67,074	$	—	$	—		$	(517,124	)	$	—

(1)

The above represents the change in the fair value of the Company’s redeemable preferred units. See the Consolidated Statements of Changes in Redeemable Convertible Units, Redeemable Non-Controlling Interest, Stockholders’ and Members’ Deficit for additional changes in the carrying value of the Company’s redeemable preferred units.

There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the years ended December 31, 2017, 2016 or 2015.

The fair value of the warrant liability related to the Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Warrants as of December 31, 2016 were:

Annual volatility			83.28		%
Annual risk-free rate			2.30		%

The fair value of the Consideration Warrants was determined using an option pricing model based on the Company’s current capitalization. Expected volatility is based on a portfolio of selected stocks of companies believed to have market and economic characteristics similar to its own. The risk-free rate is based on the yield of U.S. government securities with the same term as the option as of the valuation date. Significant inputs utilized in the valuation of the Consideration Warrants as of December 31, 2017 were:

Annual volatility			90.00		%
Annual risk-free rate			2.40		%

Changes in the unobservable inputs noted above would impact the amount of the liability for the Warrants and Consideration Warrants. For the Company’s warrants, increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Use of Estimates

Concentration of Credit Risk

Four customers represented 100% of the revenue earned during the year ended December 31, 2017. Two customers represented 100% of the revenue earned during the years ended December 31, 2016 and 2015.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted Cash and Cash Equivalents

	2017		2016
Cash and cash equivalents	$	11,758	$	51,505
Restricted cash and cash equivalents		162		—
Restricted cash and cash equivalents, long-term		2,500		—
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$	14,420	$	51,505

Collaboration Revenue and Accounts Receivable

Property and Equipment and other Long-lived Assets

The estimated useful lives of property and equipment are as follows:

Asset Category	Useful Life (in years)
Laboratory equipment	7
Computers and hardware	3-5
Furniture and office equipment	3-7
Software	3
Leasehold improvements	Shorter of useful life or remaining term of lease

Investments

Revenue Recognition

Fair Value of Financial Instruments

•

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

•

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

•

Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Research and Development

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations.

Income Taxes

Redeemable Convertible Preferred Units and Noncontrolling Interest

See discussion and additional detail of the redeemable noncontrolling interest at Note 10.

Segment and Geographic Information

Share-Based Compensation

Comprehensive Income

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

	2017		2016
Cash and cash equivalents	$	11,758	$	51,505
Restricted cash and cash equivalents		162		—
Restricted cash and cash equivalents, long-term		2,500		—
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$	14,420	$	51,505

Summary of Estimated Useful Lives of Property and Equipment

The estimated useful lives of property and equipment are as follows:

Asset Category	Useful Life (in years)
Laboratory equipment	7
Computers and hardware	3-5
Furniture and office equipment	3-7
Software	3
Leasehold improvements	Shorter of useful life or remaining term of lease

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Assumptions Used to Estimate Fair Value of Stock Option Awards Granted

	For the Year Ended December 31,
	2017		2016		2015
Expected volatility	68.72% - 85.93%		81.57% - 87.23%		83.84% - 88.23%
Expected life of option, in years	5.8 - 6.0		5.0 - 6.0		5.8 - 9.6
Risk-free interest rate	1.87% - 2.24%		1.22% - 1.45%		1.72% - 2.25%
Expected dividend yield		0.00%		0.00%		0.00%

Summary of Stock Award Activity for the Period

The following table summarizes the activity related to the stock option awards for the year ended December 31, 2017 (in thousands, except per share amounts):

	Number of Shares			Weighted- Average Exercise Price
Awards outstanding at December 31, 2016		1,096,101		$	10.68
Granted		882,000			5.77
Forfeited		(17,369	)		6.95
Awards outstanding at December 31, 2017		1,960,732		$	8.50
Options exercisable at December 31, 2017		716,787		$	10.84
Weighted average remaining contractual term	7.8 Years
Options vested and expected to vest at December 31, 2017		1,906,322		$	8.57
Weighted average remaining contractual term	8.4 Years

Summary of Activity Related to Awards of RSUs

The following table summarizes the activity related to the awards of RSUs for the year ended December 31, 2017:

	Number of Shares		Weighted- Average Grant Date Fair Value
Awards outstanding at December 31, 2016		—	$	—
Granted		35,000		5.81
Awards outstanding at December 31, 2017		35,000	$	5.81
RSUs vested and expected to vest at December 31, 2017		34,002	$	5.81

Summary of Compensation Expense Related to Grants of Stock Options

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):

	2017		2016		2015
Research and development	$	1,485	$	975	$	221
General and administrative		2,160		1,666		638
Total share-based compensation expense	$	3,645	$	2,641	$	859

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consists of the following (in thousands):

	December 31,
	2017			2016
Laboratory equipment	$	6,275		$	6,962
Leasehold improvements		1,679			2,358
Computers and hardware		323			292
Software		691			855
Furniture and office equipment		431			431
Total property and equipment		9,399			10,898
Less: accumulated depreciation and amortization		(9,116	)		(10,454	)
Property and equipment, net	$	283		$	444

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued expenses consist of the following (in thousands):

	December 31,
	2017		2016
Accounts payable	$	2,269	$	3,060
Accrued development costs		8,586		6,305
Accrued payroll related costs		1,641		1,468
Accrued other		1,405		580
Total	$	13,901	$	11,413

Notes Payable (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of Notes Payable

Notes payable consist of the following (in thousands):

	December 31,
	2017			2016
Notes payable under the Loan Agreement	$	20,000		$	12,500
Less: Debt discount		(413	)		(1,442	)
Total notes payable		19,587			11,058
Less: Current portion		(4,271	)		—
Total notes payable, net of current portion	$	15,316		$	11,058

Schedule of Principal Payments Due Under Terms of Loan Agreement

Principal payments due under the terms of the Loan Agreement are as follows (in thousands):

2018	$	4,271
2019		10,000
2020		5,729
2021		—
2022		—
Total	$	20,000

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases

Future minimum lease payments under non-cancelable operating leases as of December 31, 2017 were as follows (in thousands):

Year Ending December 31,	Operating Leases
2018	$	365
2019		371
2020		—
2021		—
2022		—
Total	$	736

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Warrant Liability [Member]

Assumptions Used to Calculate Fair Value of Consideration Warrants

Fair value of the Consideration Warrants was calculated as of December 5, 2017 using the methods described in Note 17 using the following assumptions:

Expected volatility		90.0%
Expected life of option, in years		7.0
Risk-free interest rate		2.8%
Expected dividend yield		0.00%

Fair value of the Warrants was calculated as of October 28, 2016 using the methods described in Note 17 using the following assumptions:

Expected volatility		82.54%
Expected life of option, in years		7.0
Risk-free interest rate		1.63%
Expected dividend yield		0.00%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):

	December 31,
	2017			2016			2015
U.S. statutory tax benefit	$	(18,846	)	$	(19,374	)	$	(14,387	)
Partnership income (federal) not subject to tax to the Company		13,475			13,651			12,502
Foreign withholding tax		800			—			—
State taxes (net of federal benefit)		55			—			—
Impact of the Tax Act		5,847			—			—
Change in valuation allowance		(531	)		5,723			1,885
Provision for income taxes	$	800		$	—		$	—
Effective income tax rate		-1.5	%		0.0	%		0.0	%

Schedule of Net Deferred Tax Assets/(Liabilities)

Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):

	December 31,
	2017			2016
Deferred tax assets:
Net operating loss carryforwards	$	9,023		$	8,189
Share-based compensation		—			3
Investment in partnerships		470			1,844
Charitable contributions		11			—
Total deferred tax assets		9,504			10,036
Valuation allowance		(9,504	)		(10,036	)
Net deferred tax assets	$	—		$	—

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock

	Year Ended December 31,
	2017			2016			2015
Numerator:
Net loss	$	(54,647	)	$	(55,353	)	$	(41,107	)
Less: Net loss attributable to noncontrolling interests		(38,503	)		(39,001	)		(13,609	)
Net loss attributable to vTv Therapeutics Inc., basic and diluted	$	(16,144	)	$	(16,352	)	$	(27,498	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		9,693,254			9,545,527			8,276,520
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(1.67	)	$	(1.71	)	$	(3.32	)

Schedule of Potentially Dilutive Securities Not Included in Calculation of Dilutive Net Loss per Share

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:

	Year Ended December 31,
	2017		2016		2015
Class B Common Stock ⁽¹⁾		23,119,246		23,119,246		23,655,814
Common stock options granted under the Plan		1,960,732		1,096,101		971,934
Restricted stock units		35,000		—		—
Common stock options granted under the Letter Agreement		2,283,105		—		—
Common stock warrants		388,853		152,580		—
Total		27,786,936		24,367,927		24,627,748

(1)

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Data [Abstract]

Schedule of Quarterly Financial Information

The following interim financial information presents our 2017 and 2016 results of operations on a quarterly basis (in thousands, except per share amounts):

	2017
	March 31			June 30			September 30			December 31
Revenues	$	30		$	13		$	15		$	233
Operating loss		(13,754	)		(12,615	)		(11,541	)		(12,772	)
Net loss before noncontrolling interest		(14,286	)		(13,414	)		(12,355	)		(14,592	)
Net loss attributable to vTv Therapeutics Inc.		(4,220	)		(3,963	)		(3,650	)		(4,311	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.44	)	$	(0.41	)	$	(0.38	)	$	(0.44	)

	2016
	March 31			June 30			September 30			December 31
Revenues	$	376		$	182		$	38		$	38
Operating loss		(13,540	)		(14,639	)		(13,528	)		(13,313	)
Net loss before noncontrolling interest		(13,520	)		(14,617	)		(13,505	)		(13,711	)
Net loss attributable to vTv Therapeutics Inc.		(3,852	)		(4,457	)		(3,993	)		(4,050	)
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(0.42	)	$	(0.47	)	$	(0.41	)	$	(0.42	)

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Summarizes the Conclusions Reached Regarding Fair Value Measurements

The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2017 and 2016 (in thousands):

Balance at December 31, 2017

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability, related party ⁽¹⁾

492

—

492

Total

492

—

492

Balance at December 31, 2016

Quoted Prices in Active Markets for Identical Assets

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Warrant liability ⁽²⁾

167

—

167

Total

167

—

167

(1)

(2)

	Changes in Level 3 Instruments for the years ended December 31, 2017, 2016 and 2015
	Balance at January 1		Net Change in fair value included in earnings		Net change in fair value ⁽¹⁾		Purchases / Issuance		Sales / Repurchases			Effect of Reorganization Transaction			Balance at December 31
2017
Warrant liability	$	167	$	—	$	—	$	—	$	(167	)	$	—		$	—
Warrant liability, related party		—		190		—		302		—			—			492
Total	$	167	$	190	$	—	$	302	$	(167	)	$	—		$	492

2016
Warrant liability	$	—	$	—	$	—	$	167	$	—		$	—		$	167
Total	$	—	$	—	$	—	$	167	$	—		$	—		$	167

2015
TTP Redeemable preferred units	$	412,085	$	—	$	66,379	$	—	$	—		$	(478,464	)	$	—
HPP Redeemable preferred units		—		—		—		—		—			—			—
Consideration payable		4,897		—		—		—		—			(4,897	)		—
Note payable		6,594		115		—		—		—			(6,709	)		—
Contingent distribution		26,359		—		695		—		—			(27,054	)		—
Total	$	449,935	$	115	$	67,074	$	—	$	—		$	(517,124	)	$	—

(1)

Summary of Significant Inputs Utilized in the Valuation of Warrants

Significant inputs utilized in the valuation of the Warrants as of December 31, 2016 were:

Annual volatility			83.28		%
Annual risk-free rate			2.30		%

Significant inputs utilized in the valuation of the Consideration Warrants as of December 31, 2017 were:

Annual volatility			90.00		%
Annual risk-free rate			2.40		%

Description of Business and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands		12 Months Ended
	Aug. 04, 2015 USD ($) Vote $ / shares shares	Dec. 31, 2017 USD ($) Vote $ / shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2016 USD ($) $ / shares	Jul. 29, 2015 $ / shares
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net proceeds from initial public offering			$ 105,773
Accumulated deficit		$ (279,058)		$ (215,486)
Cash and cash equivalents		$ 11,758		$ 51,505
vTv Therapeutics LLC [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC		70.50%
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC		29.50%
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Collaborative Arrangements [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Upfront payment receivable, net of foreign withholding taxes		$ 7,200
vTv Therapeutics Holdings and M&F TTP Holdings LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Description of tax receivable agreement		The Tax Receivable Agreement among the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
Amount of cash savings percentage	85.00%
MacAndrews and Forbes Group LLC [Member] \| Letter Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Funds available under related party agreement		$ 10,000
vTv Therapeutics LLC Units [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Amended and restated limited liability company agreement		two classes of membership units: (a) One managing member unit, which represents no economic interests and has 100% of the voting power of vTv LLC; and (b) Non-voting vTv Units, which represent economic interests;
Voting power percentage of one managing member unit		100.00%
Common member unit, share issued \| shares	25,000,000
Class A Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued through IPO \| shares			7,812,500
Common stock par value \| $ / shares		$ 0.01		$ 0.01	$ 0.01
Common stock, vote per share \| Vote	1	1
Class A Common Stock [Member] \| IPO [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued through IPO \| shares	7,812,500
Common stock par value \| $ / shares	$ 0.01
Common stock issued price per share \| $ / shares	$ 15.00
Net proceeds from initial public offering	$ 109,000
Class B Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of shares issued through IPO \| shares	25,000,000
Common stock par value \| $ / shares	$ 0.01	$ 0.01		$ 0.01	$ 0.01
Common stock, vote per share \| Vote	1	1

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017 USD ($) Customer Segment	Dec. 31, 2016 USD ($) Customer	Dec. 31, 2015 Customer	Dec. 21, 2017 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Accounts receivable	$ 8,000,000	$ 0
Restricted cash and cash equivalents	162,000	0
Restricted cash and cash equivalents, long-term	2,500,000
Assets held for sale	0	0
Significant interest or penalties incurred related to income taxes	$ 0
Number of reportable segments \| Segment	1
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	P3Y
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	P10Y
JDRF [Member]
Summary Of Significant Accounting Policies [Line Items]
Restricted cash and cash equivalents	$ 200,000
Reneo [Member]
Summary Of Significant Accounting Policies [Line Items]
Investments, fair value		$ 0		$ 2,500,000
Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer	4	2	2
Revenue [Member] \| Customer [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	100.00%	100.00%	100.00%

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Cash and cash equivalents	$ 11,758,000	$ 51,505,000
Restricted cash and cash equivalents	162,000	0
Restricted cash and cash equivalents, long-term	2,500,000
Total cash, cash equivalents and restricted cash and cash equivalents shown in the consolidated statement of cash flows	$ 14,420,000	$ 51,505,000	$ 88,003,000	$ 1,384,000

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2017
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	P3Y
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	P10Y
Laboratory Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	7 years
Computers and Hardware [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Computers and Hardware [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	5 years
Furniture and Office Equipment [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Furniture and Office Equipment [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	7 years
Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Leasehold Improvements [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	Shorter of useful life or remaining term of lease

Collaboration Agreements - Additional Information (Detail) - USD ($)			1 Months Ended	12 Months Ended
	Dec. 21, 2017	Mar. 06, 2015	Aug. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development				$ 39,640,000	$ 44,953,000	$ 27,237,000
Collaborative Arrangements [Member] \| Phase 2 MRCT [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum contribution amount to clinical trial				$ 3,000,000
Collaborative Arrangements [Member] \| Reneo [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront cash payment received	$ 3,000,000
License and technology transfer service period				18 months
Collaboration revenue recognized				$ 100,000
Collaborative Arrangements [Member] \| Reneo [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential development and regulatory milestone payments	94,500,000
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee received	8,000,000
Potential regulatory milestone payments based on regulatory approval	20,000,000
Potential sales-based milestones based on tiered sales of licensed products	50,000,000
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Phase 2 MRCT [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum contribution amount to clinical trial	3,000,000
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Phase 2 MRCT [Member] \| License and Technology Transfer Services of Chemistry and Manufacturing Know-How [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License and technology transfer service period				18 months
Collaboration revenue recognized				$ 100,000
Allocable arrangement consideration upfront payment	6,900,000
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Obligation to Sponsor and Conduct Portion of Phase 2 MRCT [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognized				0
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Obligation to Participate in Joint Development Committee to Oversee Development of Products and Phase 2 MRCT [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognized				0
Collaborative Arrangements [Member] \| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] \| Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential development and regulatory milestone payments	$ 25,000,000
Collaborative Arrangements [Member] \| JDRF [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum research funding receivable achievement based on research and development milestones			$ 3,000,000
Maximum funding percentage of research and development milestones			50.00%
Funding received				300,000
Research and development				$ 200,000
Restricted cash							$ 200,000
Collaborative Arrangements [Member] \| Calithera [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue recognized		$ 300,000
License fee received		$ 600,000
License agreement termination date				Dec. 21, 2017

Share-Based Compensation - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-qualified stock option awards vesting period	3 years	3 years
Non-qualified stock option awards expiration term	10 years	10 years
Compensation expense related to share-based awards	$ 3,645,000	$ 2,641,000	$ 859,000
Tax benefit related to stock option awards	0	$ 0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements	$ 4,300,000
Weighted average period to recognize unrecognized share-based compensation cost	1 year 7 months 6 days
Weighted average grant date fair value of options granted	$ 4.15	$ 4.05	$ 8.15
Aggregate intrinsic value of outstanding awards	$ 300,000
Aggregate intrinsic value of outstanding awards unvested	$ 200,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period to recognize unrecognized share-based compensation cost	2 years 4 months 24 days
Unrecognized compensation cost related to non-vested share-based compensation arrangements	$ 200,000
Aggregate intrinsic value of RSUs outstanding	$ 200,000
2015 Omnibus Equity Incentive Plan [Member] \| Class A Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares to be awarded	3,250,000

Share-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Option Awards Granted (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility	68.72%	81.57%	83.84%
Expected life of option, in years	5 years 9 months 18 days	5 years	5 years 9 months 18 days
Risk-free interest rate	1.87%	1.22%	1.72%
Maximum [Member]
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility	85.93%	87.23%	88.23%
Expected life of option, in years	6 years	6 years	9 years 7 months 6 days
Risk-free interest rate	2.24%	1.45%	2.25%

Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Share Based Arrangements To Obtain Goods And Services [Abstract]
Number of Shares, Awards outstanding, Beginning balance \| shares	1,096,101
Number of Shares, Granted \| shares	882,000
Number of Shares, Forfeited \| shares	(17,369)
Number of Shares, Awards outstanding, Ending balance \| shares	1,960,732
Number of Shares, Options exercisable \| shares	716,787
Number of Shares, Options exercisable, Weighted average remaining contractual term	7 years 9 months 18 days
Number of Shares, Options vested and expected to vest \| shares	1,906,322
Number of Shares, Options vested and expected to vest, Weighted average remaining contractual term	8 years 4 months 24 days
Weighted-Average Exercise Price, Awards outstanding, Beginning balance \| $ / shares	$ 10.68
Weighted-Average Exercise Price, Granted \| $ / shares	5.77
Weighted-Average Exercise Price, Forfeited \| $ / shares	6.95
Weighted-Average Exercise Price, Awards outstanding, Ending balance \| $ / shares	8.50
Weighted-Average Exercise Price, Options exercisable \| $ / shares	10.84
Weighted-Average Exercise Price, Options vested and expected to vest \| $ / shares	$ 8.57

Share-Based Compensation - Summary of Activity Related to Awards of RSUs (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted \| shares	35,000
Number of Shares, Awards outstanding, Ending balance \| shares	35,000
Number of Shares, RSUs vested and expected to vest \| shares	34,002
Weighted-Average Grant Date Fair Value, Granted \| $ / shares	$ 5.81
Weighted-Average Grant Date Fair Value, Awards outstanding, Ending balance \| $ / shares	5.81
Weighted-Average Grant Date Fair Value, RSUs vested and expected to vest \| $ / shares	$ 5.81

Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 3,645	$ 2,641	$ 859
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	1,485	975	221
General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 2,160	$ 1,666	$ 638

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Total property and equipment	$ 9,399	$ 10,898
Less: accumulated depreciation and amortization	(9,116)	(10,454)
Property and equipment, net	283	444
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	6,275	6,962
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	1,679	2,358
Computers and Hardware [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	323	292
Software [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	691	855
Furniture and Office Equipment [Member]
Property Plant And Equipment [Line Items]
Total property and equipment	$ 431	$ 431

Accounts Payable and Accrued Expenses - Accounts payable and accrued expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Accounts payable	$ 2,269	$ 3,060
Accrued development costs	8,586	6,305
Accrued payroll related costs	1,641	1,468
Accrued other	1,405	580
Total	$ 13,901	$ 11,413

Notes Payable - Schedule of Notes Payable (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Notes payable under the Loan Agreement	$ 20,000	$ 12,500
Less: Debt discount	(413)	(1,442)
Total notes payable	19,587	11,058
Less: Current portion	(4,271)
Total notes payable, net of current portion	$ 15,316	$ 11,058

Notes Payable - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		12 Months Ended
	Mar. 24, 2017	Oct. 28, 2016	Mar. 31, 2017	Oct. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Costs incurred in connection with loan agreement						$ 673
Allocated fair value of warrants issued						923
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Effective interest rate on note payable					17.70%
Loan and Security Agreement [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate floor				0.50%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Loan borrowed amount				$ 20,000
Debt instrument, interest rate floor				10.50%
Variable rate basis					one-month LIBOR
Interest rate description					Each loan tranche bears interest at a floating rate equal to 10.5% plus the amount by which the one-month LIBOR exceeds 0.5%.
Warrant exercise price condition					Exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants.
Warrants expiration period		7 years
Minimum cash balance required in deposit account				$ 2,500
Additional default interest rate				5.00%
Costs incurred in connection with loan agreement						700
Allocated fair value of warrants issued					$ 900	900
Interest expense related to loan agreement					$ 3,100	$ 400
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Prepayments for First 18 Months [Member]
Debt Instrument [Line Items]
Prepayment penalty fee				4.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Prepayments Thereafter [Member]
Debt Instrument [Line Items]
Prepayment penalty fee				2.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche One [Member]
Debt Instrument [Line Items]
Loan borrowed amount				$ 12,500
Debt instrument, payment terms					The Company borrowed the first tranche of $12.5 million upon close of the Loan Agreement in October 2016. The first tranche requires only monthly interest payments until May 1, 2018 followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on May 1, 2020.
Debt instrument, final payment				$ 800
Debt instrument, maturity date				May 01, 2020
Debt instrument, frequency of periodic Payment					monthly
Warrants to purchase shares of common stock		152,580
Exercise price of warrants		$ 6.39
Warrant shares percentage issued of loan amount		6.00%
Final payment, accrued additional interest expense					$ 800
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Two [Member]
Debt Instrument [Line Items]
Loan borrowed amount			$ 7,500
Debt instrument, payment terms					The Company borrowed the second tranche of $7.5 million in March 2017. The second tranche requires only monthly interest payments until October 1, 2018, followed by equal monthly payments of principal plus accrued interest through the scheduled maturity date on October 1, 2020.
Debt instrument, final payment				$ 500
Debt instrument, maturity date				Oct. 01, 2020
Debt instrument, frequency of periodic Payment					monthly
Warrants to purchase shares of common stock	38,006
Exercise price of warrants	$ 5.92
Warrant shares percentage issued of loan amount	3.00%	3.00%
Final payment, accrued additional interest expense					$ 500
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Three [Member]
Debt Instrument [Line Items]
Loan amount available for borrowing					$ 5,000
Tranches expiration date					Jun. 30, 2017

Notes Payable - Schedule of Principal Payments Due Under Terms of Loan Agreement (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
2018	$ 4,271
2019	10,000
2020	5,729
Total	$ 20,000	$ 12,500

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 28, 2007
Commitments And Contingencies [Line Items]
Lease termination description		operating leases expiring at various dates through 2019
Asset retirement obligations, noncurrent		$ 200,000	$ 200,000
Non-cancelable Operating Leases [Member]
Commitments And Contingencies [Line Items]
Rent expense for operating leases		$ 500,000	$ 600,000	$ 600,000
Facility Lease
Commitments And Contingencies [Line Items]
Lease termination year		2019
Developmental and Regulatory Milestone Payment [Member] \| Novo License Agreement [Member] \| Maximum [Member]
Commitments And Contingencies [Line Items]
Potential milestone payment					$ 115,000,000
Sales-based Milestones Payment [Member] \| Novo License Agreement [Member]
Commitments And Contingencies [Line Items]
Potential milestone payment					$ 75,000,000
Phase 2 MRCT [Member] \| Collaborative Arrangements [Member]
Commitments And Contingencies [Line Items]
Maximum contribution amount to clinical trial		$ 3,000,000
Columbia University [Member]
Commitments And Contingencies [Line Items]
Annual fee obligated to pay under the agreement	$ 100,000
Annual fee payment obligation period		2015 through 2021
Columbia University [Member] \| Regulatory Milestone Payment [Member]
Commitments And Contingencies [Line Items]
Potential milestone payment	$ 800,000

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2018	$ 365
2019	371
Total	$ 736

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Millions					12 Months Ended
	Dec. 05, 2017 USD ($) $ / shares shares	Mar. 24, 2017 $ / shares shares	Oct. 28, 2016 $ / shares shares	Aug. 04, 2015 Vote $ / shares	Dec. 31, 2017 USD ($) Vote $ / shares shares	Dec. 31, 2016 $ / shares shares	Jul. 29, 2015 $ / shares shares
Class Of Stock [Line Items]
Preferred stock, shares authorized \| shares							50,000,000
Preferred stock par value							$ 0.01
Common stock, voting rights					Holders of Class A Common Stock and Class B Common Stock will be entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval.
Change in fair value of consideration warrants expense \| $					$ 0.2
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member]
Class Of Stock [Line Items]
Warrant exercise price condition					Exercise price equal to the lower of (a) the volume weighted average price per share of the Company’s Class A Common Stock, as reported on the principal stock exchange on which the Company’s Class A Common Stock is listed, for 10 trading days prior to the issuance of the applicable Warrants or (b) the closing price of a share of the Company’s Class A Common Stock on the trading day prior to the issuance of the applicable Warrants.
Warrants expiration period			7 years
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche One [Member]
Class Of Stock [Line Items]
Warrants to purchase shares of common stock \| shares			152,580
Exercise price of warrants			$ 6.39
Warrant shares percentage issued of loan amount			6.00%
Loan and Security Agreement [Member] \| Horizon Technology Finance Corporation and Silicon Valley Bank [Member] \| Tranche Two [Member]
Class Of Stock [Line Items]
Warrants to purchase shares of common stock \| shares		38,006
Exercise price of warrants		$ 5.92
Warrant shares percentage issued of loan amount		3.00%	3.00%
Letter Agreement [Member] \| M&F Group [Member]
Class Of Stock [Line Items]
Warrants expiration date					Dec. 05, 2024
Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized \| shares					100,000,000	100,000,000	100,000,000
Common stock par value					$ 0.01	$ 0.01	$ 0.01
Common stock, vote per share \| Vote				1	1
Class A Common Stock [Member] \| Letter Agreement [Member] \| M&F Group [Member]
Class Of Stock [Line Items]
Share price	$ 4.38
Aggregate amount of common stock may be sold \| $	$ 10.0
Warrants to purchase shares of common stock \| shares	198,267
Exercise price of warrants	$ 5.04
Percentage of warrants exercisable	115.00%
Class B Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized \| shares					100,000,000	100,000,000	100,000,000
Common stock par value				$ 0.01	$ 0.01	$ 0.01	$ 0.01
Common stock, vote per share \| Vote				1	1

Stockholders' Equity - Assumptions Used to Calculate Fair Value of Consideration Warrants (Detail) - Warrant Liability [Member]			12 Months Ended
	Dec. 05, 2017	Oct. 28, 2016	Dec. 31, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected volatility	90.00%	82.54%	90.00%	83.28%
Expected life of option, in years	7 years	7 years
Risk-free interest rate	2.80%	1.63%	2.40%	2.30%
Expected dividend yield	0.00%	0.00%

Redeemable Noncontrolling Interest - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Noncontrolling Interest [Line Items]
Redemption amount of noncontrolling interest	$ 131.4	$ 122.5
Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Number of days used to determine exchange value based on weighted average price of Class A common stock	20 days
Class A Common Stock [Member] \| Exchange of Redeemable Non controlling Interest To Class A Common Stock [Member]
Noncontrolling Interest [Line Items]
Stock conversion ratio	1.00
vTv Therapeutics LLC [Member]
Noncontrolling Interest [Line Items]
Noncontrolling interest ownership percentage	70.50%

Related-Party Transactions - Additional Information (Detail)				12 Months Ended
	Dec. 05, 2017 USD ($) $ / shares shares	Apr. 23, 2010 USD ($) $ / shares shares	Apr. 17, 2007 USD ($)	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Related Party Transaction [Line Items]
Bad debt expense – related party						$ (3,000)
Reimbursement of offering costs - related party						1,329,000
Class A Common Stock [Member] \| Exchange of Redeemable Non controlling Interest To Class A Common Stock [Member]
Related Party Transaction [Line Items]
Stock conversion ratio				1.00
PharmaCore, Inc. [Member]
Related Party Transaction [Line Items]
Total purchases from related party					$ 800,000	2,300,000
Financing to related party		$ 2,900,000	$ 2,000,000
Note agreement, term		9 years
Note agreement, interest rate		8.25%
Note agreement, maturity date		Jun. 01, 2017
Capitalization of accrued interest							$ 0
Warrant exercisable term		10 years
Shares available under warrant exercised \| shares		370,370
Warrants, Exercise price per unit \| $ / shares		$ 0.54
Interest income recorded				$ 0	$ 0	400,000
Bad debt expense – related party						400,000
MacAndrews & Forbes Incorporated [Member]
Related Party Transaction [Line Items]
Ownership percentage of majority owner				78.30%
Amount of cash savings percentage				85.00%
Description of tax receivable agreement				The Tax Receivable Agreement among the Company, M&F and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
MacAndrews & Forbes Incorporated [Member] \| Letter Agreement [Member]
Related Party Transaction [Line Items]
Warrants expiration date	Dec. 05, 2024
MacAndrews & Forbes Incorporated [Member] \| Class B Common Stock [Member]
Related Party Transaction [Line Items]
Shares held by related party \| shares				23,084,267
MacAndrews & Forbes Incorporated [Member] \| Class A Common Stock [Member]
Related Party Transaction [Line Items]
Shares held by related party \| shares				2,615,666
MacAndrews & Forbes Incorporated [Member] \| Class A Common Stock [Member] \| Exchange of Redeemable Non controlling Interest To Class A Common Stock [Member]
Related Party Transaction [Line Items]
Stock conversion ratio				1.00
MacAndrews & Forbes Incorporated [Member] \| Class A Common Stock [Member] \| Letter Agreement [Member]
Related Party Transaction [Line Items]
Shares available under warrant exercised \| shares	198,267
Warrants, Exercise price per unit \| $ / shares	$ 5.04
Aggregate amount of common stock may be sold	$ 10,000,000
Share price \| $ / shares	$ 4.38
M&F Group [Member]
Related Party Transaction [Line Items]
Reimbursement of offering costs - related party						$ 1,300,000

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Compensation And Employee Benefit Plans [Abstract]
Percentage of employer contribution	50.00%
Maximum annual contribution per employee	6.00%
Contributions made by employer	$ 0.1	$ 0.2	$ 0.1

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Income tax provision		$ 800,000	$ 0	$ 0
US statutory corporate income tax rate		35.00%
Provisional decrease in deferred tax assets		$ 5,847,000
Decrease in valuation allowance		500,000
Uncertain tax positions		0
Increase decrease in uncertain tax position reasonably possible		0
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards		$ 40,200,000
Minimum [Member] \| Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date		2035
Maximum [Member] \| Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards expiration date		2037
Scenario Forecast [Member]
Income Taxes [Line Items]
US statutory corporate income tax rate	21.00%
M&F TTP Holdings LLC [Member]
Income Taxes [Line Items]
Amount of cash savings percentage		85.00%

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. statutory tax benefit	$ (18,846,000)	$ (19,374,000)	$ (14,387,000)
Partnership income (federal) not subject to tax to the Company	13,475,000	13,651,000	12,502,000
Foreign withholding tax	800,000
State taxes (net of federal benefit)	55,000
Impact of the Tax Act	5,847,000
Change in valuation allowance	(531,000)	5,723,000	1,885,000
Provision for income taxes	$ 800,000	$ 0	$ 0
Effective income tax rate	(1.50%)	0.00%	0.00%

Income Taxes - Schedule of Net Deferred Tax Assets/(Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 9,023	$ 8,189
Share-based compensation		3
Investment in partnerships	470	1,844
Charitable contributions	11
Total deferred tax assets	9,504	10,036
Valuation allowance	$ (9,504)	$ (10,036)

Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Net loss	$ (14,592)	$ (12,355)	$ (13,414)	$ (14,286)	$ (13,711)	$ (13,505)	$ (14,617)	$ (13,520)	$ (54,647)	$ (55,353)	$ (41,107)
Less: Net loss attributable to noncontrolling interests									(38,503)	(39,001)	(13,609)
Net loss attributable to vTv Therapeutics Inc.	$ (4,311)	$ (3,650)	$ (3,963)	$ (4,220)	$ (4,050)	$ (3,993)	$ (4,457)	$ (3,852)	$ (16,144)	$ (16,352)	$ (27,498)
Class A Common Stock [Member]
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted									9,693,254	9,545,527	8,276,520
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.44)	$ (0.38)	$ (0.41)	$ (0.44)	$ (0.42)	$ (0.41)	$ (0.47)	$ (0.42)	$ (1.67)	$ (1.71)	$ (3.32)

Net Loss per Share - Schedule of Potentially Dilutive Securities Not Included in Calculation of Dilutive Net Loss per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	27,786,936	24,367,927	24,627,748
Class B Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	23,119,246	23,119,246	23,655,814
Common Stock Options Granted Under the Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	1,960,732	1,096,101	971,934
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	35,000
Common Stock Options Granted Under the Letter Agreement [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	2,283,105
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share	388,853	152,580

Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Data [Line Items]
Revenue	$ 233	$ 15	$ 13	$ 30	$ 38	$ 38	$ 182	$ 376	$ 291	$ 634	$ 519
Operating loss	(12,772)	(11,541)	(12,615)	(13,754)	(13,313)	(13,528)	(14,639)	(13,540)	(50,682)	(55,020)	(38,142)
Net loss before noncontrolling interest	(14,592)	(12,355)	(13,414)	(14,286)	(13,711)	(13,505)	(14,617)	(13,520)	(54,647)	(55,353)	(41,107)
Net loss	$ (4,311)	$ (3,650)	$ (3,963)	$ (4,220)	$ (4,050)	$ (3,993)	$ (4,457)	$ (3,852)	$ (16,144)	$ (16,352)	$ (27,498)
Class A Common Stock [Member]
Quarterly Financial Data [Line Items]
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$ (0.44)	$ (0.38)	$ (0.41)	$ (0.44)	$ (0.42)	$ (0.41)	$ (0.47)	$ (0.42)	$ (1.67)	$ (1.71)	$ (3.32)

Predecessor Financial Arrangements - Additional Information (Detail) - USD ($) $ in Millions		12 Months Ended
	Aug. 28, 2015	Dec. 31, 2015	Sep. 30, 2017	Dec. 31, 2014	Dec. 30, 2014	Mar. 28, 2014	Mar. 30, 2007
M&F TTP Holdings LLC [Member] \| Note and Equity Issuance Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Outstanding principal and interest due						$ 116.2
TransTech Pharma, LLC (TTP) [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Principal amount of perpetual securities					$ 6.0
TransTech Pharma, LLC (TTP) [Member] \| Perpetual Securities [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Initial fair value of securities recorded					6.6
Increase in fair value of perpetual securities		$ 0.1
TransTech Pharma, LLC (TTP) [Member] \| M&F TTP Holdings LLC [Member] \| Series F Redeemable Convertible Preferred Units [Member] \| Note and Equity Issuance Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Redeemable convertible preferred units, issued						292,722,844
High Point Pharmaceuticals, LLC (HPP) [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Principal amount of perpetual securities					0.5
High Point Pharmaceuticals, LLC (HPP) [Member] \| M&F TTP Holdings LLC [Member] \| Series B Redeemable Convertible Preferred Units [Member] \| Note and Equity Issuance Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Redeemable convertible preferred units, issued						155,219,376
vTv Therapeutics Holdings \| Class B Common Stock [Member] \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Number of shares or units transferred	1,344,186
vTv Therapeutics Holdings \| vTv Units [Member] \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Number of shares or units transferred	1,344,186
vTvx Holdings One \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Principal amount of notes and securities repurchased	$ 6.0
vTvx Holdings One \| Class A Common Stock [Member] \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Number of shares of Class B common stock exchanged for shares of Class A common stock	1,344,186
vTvx Holdings Two \| Release Agreement [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Principal amount of notes and securities repurchased	$ 0.5
Former Officer [Member] \| High Point Pharmaceuticals, LLC (HPP) [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Percentage of ownership interest in subsidiary transferred				100.00%
Former Officer [Member] \| 2007 Note [Member] \| TransTech Pharma, LLC (TTP) [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Receivable due from a related party, net							$ 4.8
Former Officer and Related Entities [Member] \| Other Liabilities [Member]
Schedule Of Predecessor Financial Arrangements [Line Items]
Periodic cash payments to former officer and related entities, Total			$ 7.5
Cash payments to former officer and related entities at closing of the agreement					$ 2.5
Periodic cash payments to former officer and related entities			$ 5.0

Fair Value of Financial Instruments - Summary of Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	$ 167
Net Change in fair value included in earnings	190		$ 115
Purchases / Issuance	302	$ 167
Sales / Repurchases	(167)
Balance at December 31	492	167
Balance at January 1	167		449,935
Purchases / Issuance	302	167	0
Sales / Repurchases	(167)	0	0
Effect of Reorganization Transaction			(517,124)
Balance at December 31	492	167
Net change in fair value			67,074
Significant Unobservable Inputs (Level 3) [Member] \| Convertible Payable [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1			4,897
Purchases / Issuance			0
Sales / Repurchases			0
Effect of Reorganization Transaction			(4,897)
Significant Unobservable Inputs (Level 3) [Member] \| Notes Payable [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Net Change in fair value included in earnings			115
Balance at January 1			6,594
Purchases / Issuance			0
Sales / Repurchases			0
Effect of Reorganization Transaction			(6,709)
Significant Unobservable Inputs (Level 3) [Member] \| TTP Redeemable Preferred Securities [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1			412,085
Net change in fair value			66,379
Purchases / Issuance			0
Sales / Repurchases			0
Effect of Reorganization Transaction			(478,464)
Significant Unobservable Inputs (Level 3) [Member] \| HPP Redeemable Preferred Securities [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Purchases / Issuance			0
Sales / Repurchases			0
Significant Unobservable Inputs (Level 3) [Member] \| Contingent Distribution [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1			26,359
Net change in fair value			695
Purchases / Issuance			0
Sales / Repurchases			0
Effect of Reorganization Transaction			$ (27,054)
Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability, Related Party [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Net Change in fair value included in earnings	190
Purchases / Issuance	302
Balance at December 31	492
Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	167
Purchases / Issuance		167
Sales / Repurchases	(167)
Balance at December 31		167
Fair Value, Measurements, Recurring [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	492,000	167
Fair Value, Measurements, Recurring [Member] \| Warrant Liability, Related Party [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	492,000
Fair Value, Measurements, Recurring [Member] \| Warrant Liability [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total		167
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	492,000	167
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability, Related Party [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total	$ 492,000
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Total		$ 167

Fair Value of Financial Instruments - Summary of Significant Inputs Utilized in the Valuation of Warrants (Detail) - Common Stock Warrants [Member]			12 Months Ended
	Dec. 05, 2017	Oct. 28, 2016	Dec. 31, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Annual volatility	90.00%	82.54%	90.00%	83.28%
Annual risk-free rate	2.80%	1.63%	2.40%	2.30%

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	Note 12: Employee Benefit Plan The Company has a 401(k) retirement plan in which all of its full-time employees are eligible to participate. The plan provides for the Company to make discretionary 50% matching contributions up to a maximum of 6% of employees’ eligible compensation. The Company contributed $0.1 million, $0.2 million and $0.1 million to the plan for the years ended December 31, 2017, 2016 and 2015, respectively.